Follow us on Twitter
twitter icon@FreshPatents


Immune Response patents

      

This page is updated frequently with new Immune Response-related patent applications.

new patent Simultaneous analysis multiple targets using multiple metal nano-tags
The present invention relates to a simultaneous analysis method for a target using a plurality of metal nano-tags and, more particularly, to a simultaneous analysis method for a target using a plurality of metal nano-tags, wherein the method fuses a nano-particle technology on the basis of an antigen-antibody reaction, which is a conventional biological immune response, and simultaneously diagnoses a plurality of target materials by using a plurality of antigen-antibody reactions and a plurality of metal nano-tags, thereby enhancing diagnostic effect.. .
Specialty Lab Solution Bio Co., Ltd.


new patent Novel peptides and combination of peptides for use in immunotherapy against various tumors
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh


new patent Cells lacking b2m surface expression and methods for allogeneic administration of such cells
Disclosed herein are cells and populations of cells comprising a genome in which the b2m gene has been edited to eliminate surface expression of mhc class i protein in the cells or population of cells, and methods for allogeneic administration of such cells to reduce the likelihood that the cells will trigger a host immune response when the cells are administered to a subject in need of such cells.. .
President And Fellows Of Harvard College


new patent Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein
Novel nucleic acid vectors comprising sequences encoding (a) an antigen, (b) a signal peptide, and (c) a heat shock protein, are disclosed, as are methods for using such vectors to induce antigen-specific immune responses and to treat tumors.. .
The Johns Hopkins University


new patent Immunogenic composition comprising engineered alpha-hemolysin oligopeptides
The present disclosure provides immunogenic compositions useful in prevention and treatment of staphylococcus aureus infection. In particular, the present disclosure provides methods of inducing an immune response against an alpha-hemolysin-expressing s.
Integrated Biotherapeutics, Inc.


new patent Interferon-ß production modulating listeria strains and methods for using same
Mutant listeria bacteria that modulate interferon-β production are provided. The subject bacteria are characterized by having a mutation in a gene chosen from a tetr gene, a ladr gene, a virr gene, a marr gene a mdrl gene, a mdrt gene and a mdrm gene.
The Regents Of The University Of California


new patent Enzymatic immunomodulation of solid tumors and uses thereof
In some embodiments the present disclosure pertains to a method of activating an anti-tumor immune response for the treatment of a cancer. In some embodiments, such a method comprises detecting cd26 expression in a subject in need thereof.
University Of Houston System


new patent Combination of tolerogenic peptides and tfg-b for use in the induction and maintenance of oral tolerance in young mammals
This invention relates to the administration of a combination of tgf-β and one or more peptides comprising specific sequences of β-lacto-globulin. The peptides are hypoallergenic but retain the capability to induce tolerance to the native protein.
Nestec S.a.


new patent Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
The present invention is based, in part, on flagellin adjuvant used to enhance immune responses directed against streptococcus pneumoniae, in particular, to enhance immune responses to polypeptide antigens (e.g., pspa) and capsular polysaccharide from s. Pneumoniae.
Wake Forest University Health Sciences


new patent Humanized t cell mediated immune responses in non-human animals
Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized t cell co-receptor (e.g., humanized cd4 and/or cd8 (e.g., cd8α and/or cd8β)), a human or humanized t cell receptor (tcr) comprising a variable domain encoded by at least one human tcr variable region gene segment and/or a human or humanized major histocompatibility complex that binds the humanized t cell co-receptor (e.g., human or humanized mhc ii (e.g., mhc ii α and/or mhc ii β chains) and/or mhc i (e.g., mhc i α) respectively, and optionally human or humanized β 2 microglobulin). Also provided are embryos, tissues, and cells expressing the same.
Regeneron Pharmaceuticals, Inc.


Pathway specific assays for predicting irritable bowel syndrome diagnosis

The present invention provides antibodies and methods for preparing antibodies to metabolites in the serotonin, tryptophan, kynurenine pathways. The prepared antibodies have low cross-reactivity to related metabolites, and are useful reagents for specific and sensitive immunoassays the present invention also provides stable derivatives of various metabolites and short chain fatty acids.
Nestec S.a.

Method of stimulating tlr9-activated immune response

A method of stimulating a tlr9-activated immune response or enhancing a tlr9-activated immune response to an antigen is disclosed herein. Tlr9 is the cellular receptor for cpg-odn, and current developed cpg-odn has low activity to rabbit tlr9.
National Health Research Institutes

Compositions comprising chimeric antigen receptors, t cells comprising the same, and methods of using the same

Provided are isolated nucleic acid molecules encoding chimeric antigen receptors (cars) that bind to tumor antigens. Also provided are isolated polypeptides and cars encoded by the isolated nucleic acid molecules, vectors that include the isolated nucleic acid molecules, cells that include the isolated nucleic acid molecules, methods of making the same, and methods for using the same to generate a persisting population of genetically engineered t cells in a subject, expanding a population of genetically engineered t cells in a subject, modulating the amount of cytokine secreted by a t cell, reducing the amount of activation-induced calcium influx into a t cell, providing an anti-tumor immunity to a subject, treating a mammal having a muc1-associated disease or disorder, stimulating a t cell-mediated immune response to a target cell population or tissue in a subject, and imaging a muc1-associated tumor..
The University Of North Carolina At Charlotte

Novel immunomodulatory therapeutic strategies targeting tumors in cancer

The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting abcb5 and an immune checkpoint molecule related pathways using various therapeutic agents such as antibody or small molecule. The present invention also provides use of an abcb5 inhibitor and an immune checkpoint inhibitor(s) for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment of tumors..
Bioxcel Corporation

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Influenza nucleic acid molecules and vaccines therefrom

Provided herein are nucleic acid sequences that encode novel consensus amino acid sequences of ha hemagglutinin, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an immune response against one or more influenza a serotpyes using the vaccines that are provided..
The Trustees Of The University Of Pennsylvania

Compositions, methods and therapies for administering antigen peptide

The invention relates to compositions, methods and therapies for the treatment of inflammation caused by infection with propionibacterium acnes. The compositions include a combination of peptide and anti-tnf.

Early cancer detection and enhanced immunotherapy

A method of therapy for a tumor or other pathology by administering a combination of thermotherapy, immunotherapy, and vaccination optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy.

Xbp1, cd138, and cs1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions

The disclosure features, inter alia, immunogenic xbp1-, cd138-, and cs1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or waldenstrom's macroglobulinemia).
Dana-farber Cancer Institute, Inc.

Method for treating cancer

The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (mhc), or cancer, characterized by aberrant, misregulated, or increased enhancer of zeste homolog 2 (ezh2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an ezh2 inhibitor.. .
Epizyme, Inc.

Beta-glucan assay methods

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to β-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-β-glucan antibody compared to a reference standard, computing a relative antibody unit (rau) value for anti-β-glucan antibody in the sample, and identifying the subject as biomarker positive if the rau value is greater than a predetermined rau value for the biomarker anti-β-glucan antibody..
Biothera, Inc.

Dendritic cell immunotherapy

Methods of providing a targeted immune response in a subject comprising administration of a dendritic cell population are provided. In some aspects, dendritic cells are administered in conjunction with a type i interferon (inf), a tlr-7 agonist, a tlr-9 agonist, aimp1, a tlr-3 agonist, a retinoic acid inducible gene-1 (rig-1)-like receptor ligand or a cytosolic dna (cds) receptor ligand and/or are administered to a tissue site proximal to diseased tissue.
Baylor College Of Medicine

Antibodies that modulate immunity to drug resistant and latent mtb infections

The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (mdr) mtb and extremely drug resistant (xdr) mtb. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to mtb and/or antibodies that are specifically reactive to mtb antigens.
Longhorn Vaccines And Diagnostics, Llc

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies

Wherein r1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein r1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and r2 is —n+(ch3)3..

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l; (lys)m; (his)n; (orn)o; (xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Antibody-vaccine engineered constructs (avec)

Hereby, we disclose and claim, the concept, designs, enabling technologies, and utility for therapy of patients suffering from cancer, of a novel class of biomolecularly engineered, synthetic molecules: antibody-vaccine engineered constructs (avec). They comprise the main functional domains (antibodies and vaccines) and the supporting domains (linkers and reporters).
Phoenix Biomolecular Engineering Foundation

Modulation of the immune response

Methods for identifying compounds that modulate the generation of regulatory t cells (treg) in vivo and in vitro, i.e., compounds that act on the transcription factors that increase or decrease expression of foxp3.. .
The Brigham And Women`s Hospital, Inc.

Poxviral vaccines

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed..
Glaxosmithkline Biologicals, Sa

Hiv immune stimulating compositions comprising recombinantly expressed pili on bacteria and methods related thereto

This disclosure relates to recombinant bacteria, e.g. L.
Emory University

Immunogenic compositions and uses thereof

The invention relates to immunogenic compositions comprising a capsular polysaccharide (cp) from streptococcus agalactiae, commonly referred to as group b streptococcus (gbs), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against gbs and/or for reducing or preventing invasive gbs disease in subjects using the compositions disclosed herein.
Pfizer Inc.

Placental vaccination therapy for cancer

The present invention discloses methods of stimulating an immune response to cancer tissue and biological effectors used by tumors to defeat the host, through the immunization of a mammal using placental tissue, cells, molecules, and combinations thereof. In one embodiment, the invention provides the utilization of syngeneic, allogeneic, xenogeneic, and combinations thereof as immunizing sources..

Virus-like particle with efficient epitope display

The invention relates to a virus-like particle (vlp) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject.
University Of Copenhagen

Prime-boost regimens involving administration of at least one mrna construct

The present invention relates to prime-boost regimens that involve the administration of at least one mrna construct, such as the use of such constructs in “boost” administration subsequently to “prime” administration of certain other antigenic composition(s). Such inventive regimens may, in particular, be useful for the induction of an immune response in a subject, and/or the vaccination of such subject against infection from one or more pathogens, and/or the treatment or prevention of one or more diseases or conditions, including a tumour or cancer, allergy or autoimmune conditions, and/or a disease or condition associated with infection from a pathogen.
Curevac Ag

Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds

The present invention relates to the field of medical treatment of diseases and disorders, as well as the field of biomedical engineering. Embodiments of the invention relate to the delivery of irreversible electroporation (ire) through the vasculature of organs to treat tumors embedded deep within the tissue or organ, or to decellularize organs to produce a scaffold from existing animal tissue with the existing vasculature intact.
Virginia Tech Intellectual Properties, Inc.

Cdca1 epitope peptides for th1 cells and vaccines containing the same

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Longwood Gardens, Inc.

Cxcl13 as an indicator of germinal activity and immune response

Presented herein are methods of detecting and/or monitoring germinal center activity in a subject according to an amount of cxcl13 in the blood of a subject. Also presented herein are methods of determine the efficacy of a vaccine or antigen at inducing an immune response.
La Jolla Institute For Allergy And Immunology

Compositions and methods for diminishing an immune response

The invention is based upon the discovery that t regulatory type 1 (tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purify and administer tr1 cells allows for improved methods of tr1 therapies for treating a wide variety of diseases and disorders..
Fondazione Telethon

Anti-muc16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind muc16 and cd3, and uses thereof

Mucin 16 (muc16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human igg antibodies that bind to human and muc16 (monospecific antibodies).
Regeneron Pharmaceuticals, Inc.

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Variant survivin vaccine for treatment of cancer

The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (apcs) such as dendritic cells, or apc precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or apc.. .
The Wistar Institute

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Dna-based plasmid formulations and vaccines and prophylactics containing the same

The invention is a general method for improving the performance of the dna-based vaccines. The method utilizes a complex dna-generated profile of antigens to extend the effects of dna-based vaccines and to broaden the immune response.

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Immunoconjugates for programming or reprogramming of cells

The conjugate compositions and methods are useful to elicit/augment an immune response to a tumor or microbial infection or to reduce the severity of autoimmunity, chronic inflammation, allergy, asthma, periodontal disease, and transplant rejection.. .
President And Fellows Of Harvard College

Targeted cytosolic delivery of antigenic compounds

The invention relates to engineered anthrax toxin compositions that can target antigen-presenting cells such as dendritic cells. Specifically, the compositions comprise (a) a native-receptor-ablated anthrax toxin protective antigen (pa) fused to a receptor-binding moiety specific for a target receptor on a dendritic cell and (b) a lethal factor (lf) or a fragment thereof fused to an active moiety comprising at least one repeat of a disease-specific antigen.
President And Fellows Of Harvard College

Immune complex

The present invention relates to immunogenic immune complexes, related compositions, and related methods. This invention addresses the above-described un-met need by providing an immune complex (ic) or immune complexes (ics), which take advantages of type ii fc receptor (fcr) interactions and signaling to elicit broader and more potent protective immune responses.
The Rockefeller University

Mosaic vaccines for serotype a foot-and-mouth disease virus

Synthetic foot-and-mouth disease virus (fmdv) mosaic polypeptides, and nucleic acid molecules encoding the mosaic polypeptides, are described. The mosaic polypeptides have greater t-cell epitope coverage than naturally occurring fmdv polypeptides, and include common fmdv epitopes, but exclude rare fmdv epitopes.
Los Alamos National Security, Llc

Conformationally specific viral immunogens

The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine..

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods for enhancing an immune response with a ctla-4 antagonist

Methods are provided for enhancing an immune response comprising providing an immunogenic composition in conjunction with a ctla-4 antagonist. Dendritic cell populations having reduced ctla-4 expression are likewise provided..
Baylor College Of Medicine

Antibodies against human nkg2d and uses thereof

The present invention provides isolated anti-human nkg2d monoclonal antibodies useful for therapeutic applications in humans. Typically, the antibodies are fully human or humanized to minimize the risk for immune responses against the antibodies when administered to a patient.
Novo Nordisk A/s

Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof

The protein known as six-transmembrane epithelial antigen of prostate 2 (steap2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human igg antibodies that bind to human steap2 (monospecific antibodies).
Regeneron Pharmaceuticals, Inc.

Methods and compositions for activation of innate immune responses through rig-i like receptor signaling

Compositions and methods are provided that enable activation of innate immune responses through rig-i like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (pamps) that comprise elements initially characterized in, and derived from, the hepatitis c virus genome..
University Of Washington Through Its Center For Commercialization

Immunogenic composition

Methods for raising an immune response in a mammal, by administration of an immunogenic composition comprising capsular saccharides from streptococcus agalactiae (gbs) serotypes conjugated to carrier proteins.. .
Glaxosmithkliine Biologicals Sa

Immunogenic listeria-based compositions comprising truncated acta-antigen fusions and methods of use thereof

The present invention relates to compositions comprising a recombinant attenuated listeria strain expressing a truncated acta and fusion proteins thereof and methods of using the same for inducing anti-disease immune responses, and treatment of the same, including a tumor growth or cancer. In particular, the invention relates to the treatment of a tumor growth or cancer using a live attenuated recombinant listeria strain that expresses a fusion protein of a truncated acta fused to an antigen..
Advaxis, Inc.

System and imaging macrophage activity using delta relaxation enhanced magnetic resonance imaging

A magnetic resonance imaging (mri) system is provided for imaging immune response of soft tissue to therapy by, prior to therapy, administering a contrast agent to the soft tissue; imaging a region of interest using delta relaxation enhanced magnetic resonance (dremr) to define a functional section; selectively sampling local cells in the functional section; conducting immuno-assay analysis on the sampled local cells; and following therapy, further imaging said region of interest using dremr to assess immune response of said cells to therapy.. .

Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same

This disclosure provides intact bacterially derived minicells containing nucleic acids adjuvants or plasmids encoding nucleic acids adjuvants that can produce a desired immune response in target cells. This disclosure further provides methods that employ minicells to deliver nucleic acids adjuvants for use in the treatment of diseases, including neoplastic disease and cancer..
Engenelc Molecular Delivery Pty. Ltd.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Lymph node-targeting nanoparticles

Provided are nanoparticles comprising heparin, chitosan, and at least one immunomodulatory agent, e.g. A cytokine.
Duke University

Methods to improve induction of iga antibodies by vaccines

A vaccine composition is disclosed that contains a vaccine antigen and a neutrophil inhibitor in amounts effective to promote an iga response to the antigen in a subject. Also disclosed is a method for enhancing immune response to a vaccine antigen in a subject that involves co-administering to the subject the vaccine antigen and an adjuvant composition comprising a neutrophil inhibitor in an amount effective to promote an iga response to the vaccine antigen in the subject..
Ohio State Innovation Foundation

Anti-fugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides antifugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Vaccine compositions and methods of use thereof

Nanoparticle-based vaccines, compositions, kits and methods are used for the effective delivery of one or more antigens in vivo for vaccination and antibody (e.g., monoclonal antibody) production, and for the effective delivery of peptides, proteins, sirna, rna or dna to papcs or mhc class ii positive cells (e.g. Tumor cells).
University Of Miami

Compositions and methods for preventing tumor growth and treating cancer by targeting lectin galactoside-binding soluble 3 binding protein

The present invention discloses a method of treating, preventing or ameliorating tumor growth by immune response modulation via targeting lgals3bp-cd33 related siglec pathway using antibody or antibody-drug conjugate therapy. The present invention also provide use of anti-lgals3bp antibody in combination with an immune checkpoint inhibitor for enhancing, increasing, promoting, expressing, modulating desirable immune response for prevention and treatment of tumors and metastases thereof.
Bioxcel Corporation

Mosaic chimeric viral vaccine{[s]] particle

The present invention describes compositions and methods for priming protective immunity in the presence of pre-existing maternal antibody. In some embodiments, the invention contemplates simultaneously masking vaccines to avoid antibody neutralization while targeting those vaccines to specific cell types in order to elicit an enhanced immune response.
The Texas A&m University System

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods and reagents to treat autoimmune diseases and allergy

The present invention provides compositions for inducing immune tolerance and methods to modify antigen to treat disease such as autoimmune diseases and allergy. Disclosed are compositions, and related methods, comprising apc presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen.

Methods and compositions for affecting immunological responsiveness

A method of treating a subject having a deficient immune response is described. The method includes administering a therapeutically effective amount of non-immune drug, or an analog or metabolite thereof, known to induce one or more autoimmune syndromes to the subject.
Cellprint Ip Holding, Llc

Modulators of myc, and methods of using the same

Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response.
Taiga Biotechnologies, Inc.

Virotherapy with an antibody combination

Disclosed herein are viruses that can be used in methods of treatment for cancer. More specifically, the viruses express two or more antibodies which induce an effective anti-tumor immune response.
Stemimmune, Incorporated

Small molecule enhancer for dendritic cell cancer vaccines

Disclosed is a method of treating cancer, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound that inhibits a plurality of mammalian dash serine proteases. Also disclosed is a method of (a) increasing antitumor immunity, (b) stimulating or enhancing an immune response, (c) treating a condition characterized by abnormal cell proliferation, (d) increasing cytokine and/or chemokine production, or (e) stimulating or enhancing production of t-cells, in a mammal, comprising administering to a mammal in need thereof an effective amount of a compound that inhibits a plurality of mammalian dash serine proteases.
Trustees Of Tufts College

Thermostable vaccine compositions and methods of preparing same

Compositions relating to thermostable vaccines and methods of preparing same. Specifically, methods of preparing thermostable vaccines based on a recombinant ricin neurotoxin protein and uses of co-adjuvants to develop a composition capable of eliciting an immune response in a subject..
Soligenix, Inc.

Oregon Health & Science University

. .

Methods and products for evaluating an immune response to a therapeutic protein

The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a vla4 binding antibody (e.g., natalizumab)..
Biogen Ma Inc.

Cytomegalovirus vectors enabling control of t cell targeting

Cmv vectors comprising a heterologous protein antigen, an active ul131 protein (or an ortholog thereof), and an active ul128 protein (or an ortholog thereof) but lacking an active ul130 protein (or an ortholog thereof) are provided. Cmv vectors comprising a heterologous protein antigen, an active ul131 protein (or an ortholog thereof), and an active ul130 protein (or an ortholog thereof) but lacking an active ul128 protein are also provided.

Method for reducing the immune response to a biologically active protein

A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal..
Affibody Ab

Mutated salmonella enterica

A novel, mutated salmonella enterica serovar typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of s. Enterica serovars.
The United States Of America, As Represented By The Secretary Of Agriculture

Vaccines with cd40 ligand as an adjuvant

Disclosed herein is a vaccine comprising an antigen and cd40l. Also disclosed herein are methods for increasing an immune response in a subject.
Inovio Pharmaceuticals, Inc

Immunogenic fusion proteins for the treatment of cancer

Provided herein are compositions and methods for eliciting an immune response in a subject. In particular, the present disclosure is directed to immunogenic fusion proteins and methods of eliciting an immune response using host cells comprising nucleic acid molecules encoding said fusion proteins..
The Johns Hopkins University

Vaccination with anti-tick antigens to control multiple tick species and disease transmission in white-tailed deer and other host animals

Compositions of either the rm86texas protein from a texas outbreak strain of the southern cattle fever tick, rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this rm86texas protein, are effective for eliciting a protective immune response in non-bovine animals. The rm86texas protein is immunogenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a dna vaccine.
Louisiana State University

Sting (stimulator of interferon genes), a regulator of innate immune responses

Novel molecules termed sting which include nucleic acids, polynucleotides, oligonucleotides, peptides, mutants, variants and active fragments thereof, modulate innate and adaptive immunity in a subject. Sting compositions are useful for the treatment of an immune-related disorder, including treating and preventing infection by modulating immunity..
University Of Miami

Additives for animal feed

The present invention relates to the combination of organic acid salts with at least one active ingredient of plant origin, preferably essential oils, partially protected with vegetable fats and/or oils, which prevent these active ingredients from being digested by stomach enzymes during the digestive process. The sodium salts of short-chain acids, preferably salts of butyric, acid are preferred.
Norel, S.a.

Delivery of rna to trigger multiple immune pathways

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen.
Glaxosmithkline Biologicals, Sa

Methods of determining an immune response score

The present disclosure provides method for determining an immune response score (irscore), the method comprising: determining a number of differentially expressed genes that have are implicated in anti-tumor immune cell signaling/activation; determining a number of differentially expressed genes that are implicated in immunosuppression, wherein the irscore=x(low, medium, or high), wherein x is the number of differentially expressed genes that are implicated in anti-tumor immune cell signaling/activation, and wherein low refers to 1-4 differentially expressed genes that are implicated in immunosuppression, medium refers to 5-9 differentially expressed genes that are implicated in immunosuppression, and high refers to 10 or more differentially expressed genes that are implicated in immunosuppression.. .
American Molecular Laboratories Inc.

Anti-h7cr antibodies

Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the b7-h7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.. .
The Johns Hopkins University

Cdca1-derived peptide and vaccine containing same

The present invention provides cdca1-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Isg15 and its use as an adjuvant

Disclosed herein is a vaccine comprising an antigen and isg15. Also disclosed herein is a method for increasing an immune response in a subject in need thereof.
The Trustees Of The University Of Pennsylvania

Epitopes from allergen proteins and methods and uses for immune response modulation

The invention relates to common allergen proteins and peptides, subsequences, portions, homologues, variants and derivatives thereof, and methods and uses of common allergen proteins and peptides. Methods include, for example, modulating an immune response; protecting a subject against or treating a subject for an allergic response, allergic disorder or allergic disease; and inducing immunological tolerance to the allergen in a subject..
La Jolla Institute For Allergy And Immunology

Vhh constructs for diverting an immune response

The invention relates to a novel vhh construct which can be bounded by a complete antibody without impairment of the antigen binding properties of the vhh construct being impaired. The invention also relates to an antibody construct comprising a vhh construct of this type and a kit, as well as the use thereof in immunodiagnostics or in the area of therapeutics.
Preclinics Gesellschaft Fuer Praeklinische Forschung Mbh

Synthetic immunogens for prophylaxis or treatment of tuberculosis

Compositions comprising a nucleic acid molecule that encodes tb esat-6 proteins are disclosed. Methods of inducing an immune response against tb an individual are disclosed.
The Trustees Of The University Of Pennsylvania

Combination of vaccination and inhibition of mhc class i restricted antigen presentation

The present invention relates to a vaccine/inhibitor combination comprising as a vaccine at least one antigen and as an inhibitor at least one inhibitor of the major histocompatibility complex (mhc) class i restricted antigen presentation. The present invention furthermore relates to a method of vaccination of a mammal using the inventive vaccine/inhibitor combination.
Curevac Ag

Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists, and immunotoxins

This document provides novel compositions and methods utilizing immunomodulating agents that can stimulate or indirectly augment the immune system, or can have an immunosuppressive effect. Tnfr25 agonists disclosed herein have an anti-inflammatory and healing effect.
University Of Miami

Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors

The present disclosure relates to modified vaccinia ankara (mva) virus or mvaae3l delivered intratumorally or systemically as an anticancer immunotherapeutic agent, alone, or in combination with one or more immune checkpoint blocking agents for the treatment of malignant solid tumors. Particular embodiments relate to mobilizing the host's immune system to mount an immune response against the tumor..
Memorial Sloan Kettering Cancer Center

Vaccines based on hepatitis b core antigens

The invention provides a protein comprising hepatitis b core antigen (hbcag) with a sequence of the formula xpzqxr in an e1 loop, wherein x is a negatively charged amino acid residue, z is a positively charged amino acid residue, and p, q n and r are each independently an integer from 1 to 12, and wherein a sugar is attached to a z residue. The protein may comprise a first and a second copy of hbcag in tandem, wherein one or both copies of hbcag has a sugar attached to the e1 loop.
Iqur Limited

Compositions and methods for detecting, treating, and protecting against fusobacterium infection

The present invention relates to protecting against, treating, and detecting fusobacteria infections. Compositions and methods derived from nucleic acid and protein sequences of a 40 kda adhesin protein are provided to protect against, treat, and detect fusobacteria infections in a subject.
Kansas State University Research Foundation

Transcutaneous haemophilius influenzae vaccine formulations and methods

Provided are topical delivery systems and methods for treating and/or preventing a disease or disorder in a subject, or for eliciting an immune response in a subject including applying, to at least a portion of the subject's post-auricular region, a topical delivery system including a therapeutically effective amount of a topical pharmaceutical composition comprising at least one active agent and a pharmaceutically acceptable carrier and/or adjuvant. The topical pharmaceutical composition can include a topical immunogenic composition.
Research Institute At Nationwide Children's Hospital

Subunit vaccine delivery platform for robust humoral and cellular immune responses

The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed..
Cornell University

Use of agents that alter the peritumoral environment for the treatment of cancer

The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide nk1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor.
Servicio Andaluz De Salud

Recombinant aav vectors useful for reducing immunity against transgene products

The disclosure in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.. .
Suntory Flowers Limited

Live attenuated vaccines for pneumoviruses and related methods and materials

Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an m2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic.
Ohio State Innovation Foundation

Modified foot-and-mouth disease virus 3c proteases, compositions and methods thereof

This application is directed generally to foot-and-mouth disease virus (fmdv) 3c proteases that have been modified by mutating a polynucleotide sequence coding for the fmdv 3c protease. The modified fmdv proteases exhibit proteolytic activity on fmdv p1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified fmdv 3c protease on a host cell used to recombinantly produce it.
The Government Of The United States Of America, As Represented By The Secretary Of Homeland Security

Detection of t cell exhaustion or lack of t cell costimulation and uses thereof

The application relates to methods of assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and the use of such methods in determining an individual's risk of autoimmune disease progression, progression of a chronic infection, not responding to a treatment for a chronic infection, not mounting an effective immune response to vaccination, infection-associated immunopathology, transplant rejection, or cancer progression. The application also relates to in vitro methods for assessing whether cd8+ and cd4+ t cells in a sample have an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype, and for identifying a substance capable of inducing an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype in an individual, as well as a kit for assessing whether an individual has an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype or whether an exhausted cd8+ t cell or lack of cd4+ t cell costimulation phenotype is present in a sample of cd8+ and cd4+ t cells..
Cambridge Enterprise Limited

Anti-h7cr antibodies

Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the b7-h7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.. .
The Johns Hopkins University

Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

The present disclosure provides isolated monoclonal antibodies that specifically bind to lag-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human lag-3.
E. R. Squibb & Sons, L.l.c.

Compositions and methods for regulating sas1r

The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, sas1r (sperm acrosomal sllp1 receptor), which is a sperm protein receptor. Six sas1r variants, including the full length sas1r, were identified.
University Of Virginia Patent Foundation

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Class i mhc phosphopeptides for cancer immunotherapy and diagnosis

A set of phosphorylated peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of melanoma cells. They have the potential to (a) stimulate an immune response to the cancer, (b) to function as immunotherapeutics in adoptive t-cell therapy or as a vaccine, (c) to facilitate antibody recognition of the tumor boundaries in surgical pathology samples, and (d) act as biomarkers for early detection of the disease.
Agenus Inc.

Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment

Methods for inducing an immune response against human immunodeficiency virus (hiv) in hiv-infected subjects undergoing antiretroviral therapy (art) are described. The methods include administering an adenovirus vector primer vaccine and a modified vaccinia virus (mva) vector booster vaccine encoding mosaic hiv antigens..
Walter Reed Army Institute Of Research

Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Composition for treatment or prevention of infectious inflammatory diseases, or composition for immune enhancement, comprising tryptophanyl-trna synthetase as an active ingredient

The composition of the present invention can be effectively used for preventing or treating diseases of humans and animals caused by infection from bacteria, viruses or fungi and the like by inhibiting infections such as bacterial, viral, and fungal infections at an early stage particularly through activating innate immune response.. .

Listeria-based immunogenic compositions for eliciting anti-tumor responses

The present invention is directed to compositions comprising an immune checkpoint inhibitor or a t cell stimulator or a combination thereof, and a live attenuated recombinant listeria strain comprising a fusion polypeptide comprising a truncated listeriolysin o protein, a truncated acta protein, or a pest amino acid sequence fused to a tumor-associated antigen. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor or a cancer, comprising the step of administering the same..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Compositions and methods for suppressing or reducing systemic immune response in a subject

The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin d analog to a subject in need thereof..
The Trustees Of The University Of Pennsylvania

Systems and methods for targeted uvb phototherapy for dermatologic disorders and other indications

The present disclosure is directed to systems and methods for targeted uvb phototherapy for dermatologic disorders and other indications. In one embodiment, a phototherapeutic system can include a radiation source configured to emit light.
Benesol, Inc.

Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages.
Oregon Health And Science University

Method

The invention concerns a method of generating an immune response in a subject, comprising administering to the subject an antigenic molecule, a photosensitizing agent, a checkpoint inhibitor, and irradiating said subject with light of a wavelength effective to activate the photosensitizing agent to generate an immune response. Preferably the method is a method of vaccination.
Pci Biotech As

Delivery of rna to different cell types

Rna encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered rna lead to two different effects, which interact to produce a strong immune response against the immunogen.
Glaxosmithkline Biologicals, Sa

Car-expressing cells against multiple tumor antigens and uses thereof

The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., t cells, nk cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a chimeric antigen receptor (car). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a car, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine..
The Trustees Of The University Of Pennsylvania

Influenza virus vectors and uses therefor

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.

Multimodal antimicrobial therapy

The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment.
Longhorn Vaccines And Diagnostics, Llc

Urlc10-derived peptide and vaccine containing same

The present invention provides urlc10-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Immuno-regulatory lipid containing spherical nucleic acids

Immunoregulatory spherical nucleic acids (irsnas) composed of a lipid containing core and an inert nucleic non-tlr antagonistic oligonucleotide shell are provided. Acid shell these it-snas are useful for modulating an immune response..
Exicure, Inc.

Beta-catenin inhibitors in cancer immunotherapy

Provided herein are compositions and methods for the treatment of cancer by inhibition of β-catenin or a β-catenin pathway. In particular, inhibitors of β-catenin and/or the wnt/p-catenin signaling pathway are employed prevent or reverse evasion of immune response or immuno-therapy by cancers..
The University Of Chicago

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compositions and methods for enhancing an immune response

The disclosure features compounds comprising an antigen portion, a soluble major histocompatibility complex (mhc) molecule portion (e.g., all or an antigen-binding portion of a soluble mhc class i molecule), and a dynamic anchor portion (e.g., an agent, such as annexin v, that binds to phosphatidylserine). The featured compounds are useful for a variety of therapeutic applications, including, e.g., enhancing a t cell response to an antigen of interest or enhancing a t cell-driven immune response by a subject to an antigen of interest (e.g., a cancer antigen or a microbial antigen)..
The Johns Hopkins University

Molecular antigen array

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a composition comprising an ordered and repetitive antigen or antigenic determinant array.
Kuros Biosciences Ag

Anti-tumor vaccine derived from normal cells

A composition for inducing an immune response in a mammal, comprises lymphoid cells in which expression of tumor antigens has been chemically induced. The tumor antigens are induced in proliferating normal lymphoid cells, especially during the log phase of proliferation.
Cytovac A/s

Rna containing compositions and methods of their use

The present invention relates to a composition comprising an isolated, single stranded rna molecule having a nucleotide sequence comprising 20 or more bases and a pattern of cpg dinucleotides defined by a strength of statistical bias greater than or equal to zero, and a pharmaceutically acceptable carrier suitable for injection. The present invention also relates to a kit comprising a cancer vaccine and the composition of the present invention as an adjuvant to the cancer vaccine.
Ecole Normale Superieure

Method for treating hiv

The present invention provides novel processes for regulating immune responses in mammalian subjects, e.g., humans, afflicted with diseases such as cancers, infections, e.g., viral infections, bacterial infections, or immune dysfunctions, especially auto-immune disorders, e.g., diabetes, crohn's disease, rheumatoid arthritis, arteriosclerosis and ulcerative colitis. More particularly, this invention relates to generating elevated levels of an intermediary metabolite, e.g., lipids or conjugated biomolecules, e.g., glycolipids, lipoproteins and glycoproteins other than antibodies, cytokines or hormones.
Enzo Therapeutics, Inc.

Cholera toxin chimera and its use as a staph vaccine

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from s.
Hogenboom Phloxen

Modified antibody

Recombinant antibody-based molecules that trigger both t-cell and b-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif.
Vaccibody As

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compounds and methods to suppress autoimmune response

A composition and method for treating autoimmune disease includes administering an effective amount of an aryl hydrocarbon receptor (ahr) ligand. The ahr ligand includes 11-cl-bbq, 10-cl-bbq, an analog of 11-cl-bbq, or combination thereof.
Oregon State University

Synthetic glucopyranosyl lipid adjuvants

Or a pharmaceutically acceptable salt thereof, wherein l1. L2, l3, l4, l5, l6, l7, l8, l9, l10, y1,y2, y3, y4, r1, r2, r3 , r4, r5, r6, are as defined herein.

Polyelectrolyte multilayers assembled from immune signal compounds

Immune-polyelectrolyte multilayers (ipems) that can be made entirely from immune signal compounds are provided. Ipems are formed from first layer of a first immune signal compound, and a second layer of the first immune signal compound or a second immune signal compound disposed on the first layer of the first immune signal compound.
University Of Maryland, College Park

Proteins comprising mrsa pbp2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat mrsa infections

Nucleic acid molecules which encode an mrsa pbp2a protein or a fragment thereof which comprises at least 245 amino acid are disclosed. Compositions comprising the nucleic acid molecules are disclosed.
The Trustees Of The University Of Pennsylvania

Immunogenic/therapeutic glycan compositions and uses thereof

The present disclosure encompasses immunogenic/therapeutic compositions including globo series antigens (ssea-4, globo h or ssea-3) glycoconjugates and therapeutic adjuvants (obi-821 or obi-834) as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier.
Obi Pharma, Inc.

Immunotherapeutic vaccine and antibody combination therapy

The present invention relates to a combination product, composition(s) and kit of parts comprising at least (i) a therapeutic vaccine and (ii) one or more immune checkpoint modulator(s). The present invention also concerns a method for treating a proliferative or an infectious disease as well as a method for eliciting or stimulating and/or re-orienting an immune response, wherein said methods comprise administering to a subject in need thereof said combination product or said composition(s)..
Transgene Sa

Administration of plant expressed oral tolerance agents

Protein replacement therapy for patients with hemophilia or other inherited protein deficiencies is other complicated by pathogenic antibody responses, including antibodies that neutralize the therapeutic protein or that predispose to potentially life-threatening anaphylactic reactions by formation of ige. Using murine hemophilia b as a model, we have developed a prophylactic protocol against such responses that is non-invasive and does not include immune suppression or genetic manipulation of the patient's cells.
The Trustees Of The University Of Pennsylvania

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Bispecific binding proteins and uses thereof

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein.
Medimmune, Llc

Antibodies to l-type voltage gated channels and related methods

Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of l-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.. .
Biommune Technologies Inc.

Cytomegalovirus-based vaccine expressing ebola virus glycoprotein

A recombinant herpesvirus-based vector comprising a nucleic acid sequence encoding a heterologous antigen and a promoter for controlling the expression of the antigen, in which the promoter is expressed at a time selected to provide a required immune response in a subject.. .
The Regents Of The University Of California

Methods and compositions for attenuated chlamydia as vaccine and vector

The present invention provides chlamydia organisms and compositions and methods of use in the treatment/prevention of chlamydial infection in a subject, for eliciting an immune response in a subject and for use as vectors.. .
Board Of Regents, The University Of Texas System

Methods and compositions for inducing an immune response to egfrviii

The present invention relates to methods of inducing a t-cell response against a egfrviii in a subject. These method comprise administering to a subject a composition which expresses at least one immunogenic polypeptide, the amino acid sequence of which comprise a plurality of egfrviii polypeptide sequences, the sequence of which each comprise eekkgnyv (seq id no: 3), and/or administering the polypeptide itself..
Providence Health & Services - Oregon D/b/a Providence Portland Medical Center

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Tnfrsf-binding agents and uses thereof

Polypeptides and agents that bind a tnf receptor superfamily protein are disclosed, particularly agents that specifically bind gitr, ox40, or cd40. The polypeptides or agents may include fusion polypeptides, particularly polypeptides comprising gitrl, ox40l, or cd40l and/or bispecific agents.
Oncomed Pharmaceuticals, Inc.

Methods of modulating immune and inflammatory responses via administration of an algal biomass

An algal biomass and supernatant derived from at least one species of algae exhibits anti-inflammatory and immune response modulating properties. Methods of reducing the symptoms of or treating a condition or disease in an animal, including bovine mastitis and bovine respiratory disease complex, and the pain and discomfort caused by osteoarthritis, injury or overexertion or muscle and connective tissue strains, comprises administering to the animal in need thereof an algal biomass or supernatant derived from at least one species of algae, or an extract, derivative or biologically active compound derived from the algae species, biomass or supernatant, or compositions thereof..
Zivo Bioscience, Inc.

Inhibition of yap for breaking tumor immune tolerance

Yes-associated protein (yap), a downstream co-activator of the hippo pathway, is highly expressed in the treg cell subset, and is critical to maintain its suppressive activity. Originally discovered in drosophila melanogaster, the hippo signaling pathway is a major regulator of cellular growth and proliferation in mammals.
The Johns Hopkins University

Novel multivalent nanoparticle-based vaccines

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus.
The Usa, As Represented By The Secretary Department Of Health And Human Services

Compositions and methods for improved skin care

Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen..

Genetic factors associated with inhibitor development in hemophilia a

The present invention provides methods for predicting the risk of an individual developing antibodies to factor viii by identifying a single nucleotide polymorphism of an immune response or immune modifier gene. The invention further provides oligonucleotides, diagnostic kits, microarrays, and isolated nucleic acids comprising single nucleotide polymorphisms of immune response or immune modifier genes..

Method for rapid in vitro synthesis of bioconjugate vaccines via recombinant production of n-glycosylated proteins in prokaryotic cell lysates

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines.
Cornell University

Recombinant cytomegalovirus vectors as vaccines for tuberculosis

The present disclosure provides cytomegalovirus vectors encoding fusion proteins comprising mycobacterium tuberculosis (mtb) antigens, nucleic acid molecules encoding the same, cytomegalovirus vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.. .
Oregon Health And Science University

Fcrn antibodies and methods of use thereof

The present invention features antibodies that have high binding affinity to human neonatal fc receptor (fcrn). These anti-fcrn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, and to treat immunological diseases (e.g., autoimmune diseases) in a subject..
Momenta Pharmaceuticals, Inc.

Synthetic nanoparticles for delivery of immunomodulatory compounds

The present disclosure provides a synthetic nanoparticle comprising a peptide nucleic acid (pna) oligomer conjugated to a lipid, wherein the pna oligomer noncovalently complexes with an immunomodulatory compound, thereby forming a nanoparticle. The nanoparticles are useful to elicit immune responses and can be used to treat a broad range of cancers and infectious diseases..
Massachusetts Institute Of Technology

Checkpoint inhibitor and vaccine combinations and use of same for immunotherapy

Disclosed herein is a vaccine comprising an antigen and checkpoint inhibitor. Also disclosed herein is a method for enhancing an immune response in a subject.
Inovio Pharmaceuticals, Inc.

In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus-like particles

The invention relates to the finding that stimulation of antigen presenting cell (apc) activation using substances such as anti-cd40 antibodies or dna oligomers rich in non-methylated c and g (cpgs) can dramatically enhance the specific t cell response obtained after vaccination with recombinant virus like particles (vlps) coupled, fused or otherwise attached to antigens. While vaccination with recombinant vlps fused to a cytotoxic t cell (ctl) epitope of lymphocytic choriomeningitis virus induced low levels cytolytic activity only and did not induce efficient anti-viral protection, vlps injected together with anti-cd40 antibodies or cpgs induced strong ctl activity and full anti-viral protection.
Kuros Biosciences Ag

Attenuated pasteurella multocida vaccines & methods of making & use thereof

The present invention provides attenuated p. Multocida strains that elicit an immune response in animal p.
Merial Inc.

Polymer particles and uses thereof

The present invention relates to polymer particles and uses thereof. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof in eliciting a cell-mediated immune response and in the treatment or prevention of diseases or conditions including those caused by intracellular pathogens..
Polybatics Limited

Stimulation of an immune response by enantiomers of cationic lipids

A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (i); wherein in r1 is a quaternary ammonium group, y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, c* is a chiral carbon, r2 and r3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof..
Pds Biotechnology Corporation

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Klemm+sohn Gmbh & Co. Kg

Method and compositions for cellular immunotherapy

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring cd8+ central memory t cells or combinations of central memory t cells with cd4+ t cells that are genetically modified to express a chimeric receptor. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a poly nucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain.
Seattle Children's Hospital (dba Seattle Children's Research Institute)

Alternative nucleic acid molecules containing reduced uracil content and uses thereof

The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mrna wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response.
Modernatx, Inc.

Nucleic acids for treatment of allergies

The present invention provides dna vaccines for the treatment of allergies. The vaccines comprise the coding sequence for one or more allergenic epitopes, and preferably the full protein sequence, of the allergenic protein from which the epitope(s) is derived, fused inframe with the lumenal domain of the lysosomal associated membrane protein (lamp) and the targeting sequence of lamp.
Immunomic Therapeutics, Inc

Modulation of antigen immunogenicity by deleting epitopes recognized by nkt cells

The invention describes a method and compounds for the prevention of immune responses towards allofactors, towards viral vectors used for gene therapy and gene vaccination, towards proteins to which subjects are naturally exposed, towards genetically-modified organisms and towards undesirable effects related to vaccine administration for allergic or infectious diseases.. .
Imnate Sarl

Lipid a mimics, methods of preparation, and uses thereof

The invention provides lipid a mimics in which one or both of the sugar residues of a natural lipid a disaccharide backbone has been replaced with an aromatic group. These lipid a mimics may further differ from a natural lipid a molecule with respect to other structural characteristics, such as, a different number of phosphate groups present, changes in the number, structure and location of lipid chains and/or changes in the spacing and linkage of the sugar residues (or their aromatic replacements).
Immunovaccine Technologies Inc.

Alum-containing coating formulations for microneedle vaccine patches

Compositions for coating microneedles with aluminum-adjuvanted vaccines are provided comprising an aluminum-containing wet gel suspension selected from aluminum hydroxide wet gel suspension and aluminum phosphate wet gel suspension; a vaccine in an amount effective to stimulate an immune response in a mammal; a sugar, sugar alcohol, or combinations thereof; and a thickener. Some embodiments of the compositions have a viscosity of 500 to 30,000 cps when measured at 100 s−1 and temperature of 25 c.
3m Innovative Properties Company

Adjuvant composition containing at least one influenza virus neutralizing and binding molecule and vaccine composition containing same

This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses..
Celltrion Inc.

Methods and compositions for induction of immune response

The invention provides a substantially antigen-free composition for induction of innate immune response in a bird or a mammal, the composition comprising a saponin, a sterol, a quaternary amine, and a polyacrylic polymer to the mammal or bird. Methods of using the composition are also provided..
Zoetis Services Llc

Recombinant metapneumovirus f proteins and their use

Metapneumovirus (mpv) f proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the mpv f proteins and/or nucleic acid molecules can be used to generate an immune response to mpv in a subject.
Institute For Research In Biomedicine

Influenza virus vaccination regimens

Provided herein are immunization regimens for inducing an immune response (e.g., an antibody response) against influenza virus. In specific aspects, the immunization regimens involve the administration of a chimeric hemagglutinin (ha), a headless ha or another influenza virus stem domain based construct (e.g., the ha stem domain or a fragment thereof) to a subject.
Icahn School Of Medicine At Mount Sinai

Method and compositions for enhancing immunotherapeutic treatment of a cancer

Provided are methods and compositions for enhancing treatment of a cancer by administering a therapeutic agent for the treatment of a cancer together with a second agent that elevates the level of protein p53. The second agent generates in the tumor a population of dendritic cells expressing at least one of batf3, irf5, cd103, and xcr1.
Augusta University Research Institute, Inc.

Autologous tumor vaccines and methods

Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.. .
Vaccinogen, Inc.

Sheep nematode vaccine

The present invention is based upon the identification of a number of antigens derived from species of the genus teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate teladorsagia infections/infestations..
Moredun Research Institute

Methods for enhancing efficacy of therapeutic immune cells

The present invention relates to a method of using a receptor (e.g., chimeric antigen receptor—car) that activates an immune response upon binding a cancer cell ligand in conjunction with a target-binding molecule that targets a protein or molecule ci for removal or neutralization to generate enhanced anti-cancer immune cells. The present invention also relates to engineered immune cells having enhanced therapeutic efficacy and uses thereof..
National University Of Singapore

Human ebola virus species and compositions and methods thereof

Compositions and methods including and related to the ebola bundibugyo virus (ebobun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from ebobun challenge in a subject such as a primate.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents

The present invention relates to methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents.. .
Dana-farber Cancer Institute, Inc.

Amino acid and peptide conjugates and uses thereof

The present invention relates to peptides, and amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the peptides and conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the peptides and conjugates for the same, and uses of the peptides and conjugates in the manufacture of medicaments for the same.. .

Device and administering an anti-cancer substance

An anti-cancer substance is administered via the patient's blood ex vivo and in line by establishing a connection between the patient and a device having a chamber containing the anti-cancer substance. The patient's blood in the chamber and the anti-cancer substance interact so that immune cells in the blood (1) are activated to produce an immune response in the patient, or (2) are pre-armed by attaching to the cells antibodies, or (3) both.

Method and device for treating cancer

A method and device treats cancer where blood from a cancer patient passes through an array of passageways within an interior of a chamber. The passageways include wells having porous membrane wall portions that enable a molecular-sized activating agent in a carrier fluid that enhances an immune response to pass through these porous wall portions.

Genetically modified mesenchymal stem cells expressing alpha-1 antitrypsin (aat)

Genetically modified mesenchymal stem cells can be used as a medicament in the treatment of medical conditions associated with inflammation and/or an unwanted immune response in subjects without an alpha1-antitrypsin (aat) deficiency. The stem cells include an exogenous nucleic acid, which includes (i) an alpha-1 antitrypsin (aat) encoding region operably linked to (ii) a promoter or promoter/enhancer combination..
Apceth Gmbh & Co. Kg

Methods of inducing an immune response to hepatitis c virus

The present disclosure provides methods for inducing an immune response to hepatitis c virus (hcv) in an individual. The present disclosure provides methods for treating an hcv infection in an individual..

Viral rna segments as immunomodulatory agents and vaccine components

The disclosure provides compositions and methods involving viral rna segments for use in modulating immune responses, including inhibition inflammation related to pathogenic t-cell activation. In addition, modification of the viral sequences responsible for modulating immune response provides for improved vaccine formulations..
The University Of Iowa Research Foundation

Imp-3 epitope peptides for th1 cells and vaccines containing the same

Isolated imp-3-derived epitope peptides having th1 cell inducibility are disclosed herein. In preferred embodiments, such a peptide of the present invention can promiscuously bind to mhc class ii molecules and induce imp-3-specific cytotoxic t lymphocytes (ctls) in addition to th1 cells.
Oncotherapy Science, Inc.

Methods for profiling the t cell repertoire

The present disclosure relates to methods for profiling subject specific and personalized t cell receptor (tcr) repertoires using a single-cell sequencing method. More particularly, disclosed are methods for determining binding of t cell receptors to subject specific neoantigens.
Dana-farber Cancer Institute, Inc.

Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity

Provided are polynucleotides and viral vectors, particularly, alphavirus vectors such as sindbis viral vectors, which encode multiple, e.g., two or more, epitopes of at least one tumor associated antigen in which each epitope is separated by a processing or enzyme cleavage site. The multiple epitopes of the two or more tumor associated antigens encoded by the described polynucleotides and viral vectors may be the same or different.
New York University

Methods for immunomodulation of cancer and infectious disease therapy

The present invention provides methods for modulating the immune response of a subject to a therapeutic agent, the method comprising administering an effective amount of a triphenylethylene (trip) compound with an effective amount of the therapeutic agent. In particular embodiments, the trip compound enhances the immune response of the subject to the therapeutic agent.
The Regents Of The University Of California

Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine

Vaccine compositions that may be administered to a subject via the buccal and/or sublingual mucosa are provided. Methods for administration and preparation of such vaccine compositions are also provided..
Board Of Regents, The University Of Texas System

Compositions and methods related to neurological disorders

The present technology relates to compositions comprising inulin particles for use in the enhancement of immune responses to neuronal self-antigens for treating or preventing neurodegenerative diseases, in a subject. Also provided are pharmaceutically acceptable compositions comprising: particles of inulin; a substance comprising one or more pathogen-associated molecular patterns (pamps); and a neuronal self-antigen fused to carrier, and methods and uses of the composition for inducing or modulating an immune response in a subject, such as modulating an immune response to a neuronal self-antigen as a vaccine.
Terra Nova Nurseries, Inc.

Fully stabilized asymmetric sirna

Provided herein are self-delivering oligonucleotides that are characterized by efficient risc entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.. .
University Of Massachusetts

Compositions and methods related to protein a (spa) variants

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria.
The University Of Chicago

Tissue targeted antigenic activation of the immune response to treat cancers

The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated.. .
Qu Biologics Inc.

Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza

The present invention provides co-administration (for example, immunogenic cocktail compositions and/or prime-boost regimens) of computationally optimized h1n1 influenza hemagglutinin (ha) polypeptides. Co-administration of the optimized h1n1 influenza hemagglutinin (ha) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to diverse and multiple h1n1 influenza virus strains, including both seasonal and pandemic strains..
Sanofi Pasteur, Inc.

Methods and compositions for inhibiting polyomavirus-associated pathology

Disclosed herein are methods of eliciting an immune response against a polyomavirus (for example, bkv serotype i (bkv-i), bkv serotype ii (bkv-ii), bkv serotype iii (bkv-iii) and/or bkv serotype iv (bkv-iv)) and methods of treating or inhibiting polyomavirus-associated pathology (such as polyomavirus-associated nephropathy, bkv-associated hemorrhagic cystitis, or jc virus-associated progressive multifocal leukoencephalopathy; pml). Further disclosed are immunogenic compositions of use in the disclosed methods.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

Methods and compositions for ebola virus vaccination

Methods for generating immune responses to ebola virus antigens using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Combination of listeria-based vaccine with anti-ox40 or anti-gitr antibodies

Disclosed herein are compositions comprising use of compositions comprising a live attenuated recombinant listeria strain comprising a fusion protein of a truncated listeriolysin o (llo) protein, a truncated acta protein, or a pest amino acid sequence fused to a heterologous antigen, including a tumor-associated antigen, wherein the compositions further comprise or are co-administered with an antibody or fragment thereof. Also disclosed are combination therapies comprising use of these compositions comprising live attenuated recombinant listeria strains, in conjunction with an antibody or fragment thereof for use in treating, protecting against, and/or inducing an immune response against a tumor, especially wherein the treating, protection against and/or inducing an immune response increases percent survival in a subject..
Augusta University Research Institute, Inc.

Immunomodulation by iap inhibitors

The present invention is directed to immune adjuvants containing iap inhibitors, including smac mimetics. The invention further provides pharmaceutical compositions and vaccines containing an iap inhibitor and an antigen.
Dana-farber Cancer Institute, Inc.

Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions

The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5′ region nucleotides present in the 5′ edge of the gene ns1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein e of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein e level and of constructural ns1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigene in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the flavivirus and/or other patogens..
Gardengenetics Llc

Characterization of adaptive immune response to vaccination or infection using immunosequencing

Methods of monitoring and measuring dynamic adaptive immune cell responses are provided. High-throughput sequencing of t cell receptor and immunoglobulin loci is used to characterize the breadth of an effector cell response to a stimulus, such as a vaccine or infection.
Fred Hutchinson Cancer Research Center

Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy

The present invention relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35.

Gpc3 epitope peptides for th1 cells and vaccines containing the same

Isolated gpc3-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Tuberculosis compositions and methods of treating or preventing tuberculosis

The present disclosure provides fusion proteins comprising mycobacterium tuberculosis (mtb) antigens, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of eliciting an immune response against tuberculosis.. .
Aeras

Hiv vaccine formulation

Immunogenic compositions containing a human immunodeficiency virus (hiv) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant.
Janssen Vaccines & Prevention B.v.

Calcium flux agonists and methods therefor

Calcium flux agonists are used to enhance a tlr- or nod-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include ca2+ ionophores and serca inhibitors and are used in synergistic quantities where a ligand to a tlr or nod receptor is present..
Nant Holdings Ip, Llc

Method and compositions for the prevention and treatment of a hiv infection

Described herein are methods of preventing or treating a hiv infection comprising administering to a mammal in need thereof, a pharmaceutically effective amount of a cd8+ t cell vaccine composition. Such methods comprising using cd8+ t cells which have been pre-stimulated with at least one hiv epitope, to thereby enhance a cd8+ t cell immune response against hiv in said mammal..
The Johns Hopkins University

Nanoemulsion respiratory syncytial virus (rsv) subunit vaccine

The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (rsv) surface proteins, fusion (f) and glycoprotein (g) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.. .
Nanobio Corporation

Novel tilapia virus and uses thereof

The invention is directed to isolated tilapia lake virus or tilv, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from tilv, and use of these reagents for detecting the presence or absence of tilv in an animal.
Kimron Veterinary Institute

Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis

The present invention relates to compositions and methods for immunotherapy of a subject afflicted with diseases such as cancer, an infectious disease, or a neurodegenerative disease, which methods comprise administering to the subject a composition comprising a therapeutically effective amount of an anti-pd-l1 antibody or portion thereof that potentiates an endogenous immune response, either stimulating the activation of the endogenous response or inhibiting the suppression of the endogenous response.. .
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Compositions and methods for modulating salm5 and hvem

The invention provides compositions and methods for regulating immune responses. In one embodiment, compositions of the invention include one or more salm5-hvem antagonists that are able to induce inflammation in the cns or an immune privileged tissue.
Yale University

Vaccine compositions containing modified zika virus antigens

The present disclosure relates to vaccine compositions that comprise a zika virus antigen and an adjuvant. The present disclosure also provides methods for inducing a protective immune response by administering the disclosed vaccine compositions in a subject in needs thereof.
Novavax, Inc.

Boehringer Ingelheim Vetmedica S.a. De C.v.

. .

Compositions and methods for treatment of cytomegalovirus

The present disclosure provides compositions and methods useful for treating hcmv infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (vlps) which comprise one or more moloney murine leukemia virus (mmlv) core proteins and include one or more hcmv epitopes, such as, for example, from hcmv envelope glycoproteins gb and/or gh and/or tegument protein pp65.
Variation Biotechnologies Inc.

Disaccharide synthetic lipid compounds and uses thereof

Essentially pure compounds of the formulas (i) to (v) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided.
Ac Immune Sa

Immunonanotherapeutics providing a th1-biased response

Disclosed are synthetic nanocarrier compositions, and related methods, for treating diseases in which generating a th1-biased immune response is desirable.. .
Selecta Biosciences, Inc.

Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes

The present disclosure relates to adenovirus protein modifications to augment immune response to a transgene of a recombinant adenovirus and to circumvent pre-existing anti-adenovirus immunity. Some embodiments are directed to a recombinant adenovirus derived from a recombinant adenovirus plasmid vector, wherein the recombinant adenovirus plasmid vector comprises a nucleotide sequence encoding a plasmodium circumsporozoite protein, or antigenic portion thereof, operably linked to a heterologous promoter and a modified capsid or core protein, wherein an immunogenic epitope of plasmodium circumsporozoite is inserted into or replaces at least part of a capsid or core protein.
The Rockefeller University

Vaccination methods

In one aspect, a method of treating cancer in a mammal is provided. The method comprises administering to the mammal an oncolytic vector that expresses a tumour antigen to which the mammal has a pre-existing immunity.
Turnstone Limited Partnership

System and delivering genetic material or protein to cells

It has been established that bacterial hybrid vectors including prokaryote cells modified by the addition of cationic polymers to the outer surface of the cell can selectively deliver exogenous cargos, such as nucleic acids, polypeptides and small molecules to an eukaryotic cell, such as an antigen presenting cell. Compositions and methods for the delivery and expression of nucleic acids and polypeptides to eukaryotic cells are described.
The Research Foundation For The State University Of New York

Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis

Provided are methods of enhancing an immune response and methods for reducing the recruitment of monocytes to a lymph node by administering to an individual an angiotensin ii receptor blocker or a compound of formula (i) in conjunction with an antigen. The invention also provides relate methods for amplifying vaccine immunity by administering to an individual an angiotensin ii receptor blocker or a compound of formula (i) in conjunction with an vaccine.
Colorado State University Research Foundation

Probiotic augmentation of anti-tumor endothelium immune responses

Augmenting or stimulating an immune response, to tumor endothelial cells, by: a) obtaining a tumor endothelial antigen or composition of antigens; b) administering said tumor endothelial antigen or composition of antigens in an immunogenic manner to a host; and c) providing a probiotic and/or prebiotic mixture to said host being immunized.. .
Batu Biologics, Inc.

Recombinant self-replicating polycistronic rna molecules

This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies.
Glaxosmithkline Biologicals, Sa

Novel peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Contructs for enhancing immune responses

Chimeric protein constructs including a herpesvirus glycoprotein d (gd) and a heterologous polypeptide that interact with herpes virus entry mediator (hvem) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided.. .
The Wistar Institute Of Anatomy And Biology

Methods and compositions for enhancing immune responses

Compositions and methods are described for generating an improved effective immune response against an immunogen in humans. The enhanced immune response, is obtained by using an mva vector as a prime and an adenovirus vector as a boost and is characterized by a high level of antibody response specific to the immunogen, and an enhanced cellular immune response.
The United Of America, As Represented By The Secretary, Department Of Health And Human Services

Treatment for cutaneous t cell lymphoma

The present invention provides method for treating a patient with cutaneous t cell lymphoma (ctcl). Generally, the methods include administering to the patient an irm compound in an amount effective to ameliorate at least one symptom or clinical sign of ctcl.
3m Innovative Properties Company

Multivalent stable vaccine composition and methods of making same

Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual..
Anthura B.v.

. .

Compositions and methods for treating clostridium difficile infection

Clostridium difficile is the most common hospital acquired pathogen in the united states, and infection is in many cases fatal. Toxins a and b are its major virulence factors, but increasingly a third toxin may be present, known as c.
University Of Virginia Patent Foundation

Immunogenic wt-1 peptides and methods of use thereof

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a wt-1-expressing cancer, comprising peptides derived from the wt-1 protein.. .
Memorial Sloan Kettering Cancer Center

Lipidated immune response modifier compound compositions, formulations, and methods

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .
3m Innovative Properties Company

Poxviral vaccines

The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed..
Glaxosmithkline Biologicals, Sa

Size tunable microbial mimetics for immunotherapy of cancer

The mm exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses. The mm constitute a versatile platform for triggering immune responses against cells expressing epitopes contained within the complexed antigenic cargo..

Target peptides for immunotherapy and diagnostics

A set of target peptides are presented by hla a*0101, a*0201, a*0301, b*4402, b*2705, b*1402, and b*0702 on the surface of disease cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., cancer, (b) to function as immunotherapeutics in adoptive t cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/mhc complex..
The University Of Birmingham

Koc1-derived peptide and vaccine including same

The present invention provides koc1-derived epitope peptides having the ability to induce cytotoxic t cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic t cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or ctls.
Oncotherapy Science, Inc.

Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient

The present invention relates to a biguanide derivative compound capable of effectively preventing and treating immune diseases. The biguanide-based derivative compound according to the present invention inhibits the generation of il-17 and tnf-α, which are inflammatory cytokines, increases the activity of regulatory t cells having an immunomodulatory function, and exhibits excellent therapeutic effects in animal models of immune diseases.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Cross-protective pathogen protection, methods and compositions thereof

The present disclosure provides a method of inducing a cross-protective immune response in a subject against a pathogen, such as influenza, comprising administering a first unique pathogen antigen to the subject; and administering a second unique pathogen antigen 3-52 weeks after a); wherein the second unique pathogen antigen and the first unique pathogen antigen are immunologically distinct but share conserved sites that are not normally immunogenic for antibodies. Also disclosed herein are assays for detecting cross-protective antibodies, methods of generating novel cross-protective antibodies.

Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an rsv nucleocapsid protein.
Bavarian Nordic A/s

Human papilloma virus constructs

Embodiments of the present invention provide compositions and methods for recombinantly generating tagless constructs of proteins or peptides. In certain embodiments, recombinant proteins or peptides disclosed herein concern human papilloma virus (hpv).
The Regents Of The University Of Colorado, A Body Corporate

Non-lipidated variants of neisseria meningitidis orf2086 antigens

The present invention relates to compositions including an isolated non-pyruvylated non-lipidated orf2086 polypeptide, and methods thereof. In an exemplary embodiment, the compositions described herein are immunogenic.
Wyeth Llc

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Nlrc5 as a biomarker for cancer patients and a target for cancer therapy

The invention pertains to biomarkers for identifying a cancer that is likely or not likely to evade the immune system of a subject, thus, is likely or not likely to show better prognosis (prognostic biomarker) and/or better responses to cancer therapies (predictive biomarker). The invention provides a method of identifying a subject as having a cancer that is likely to evade the immune system of the subject based on one or more of the following biomarkers in the cancer cells of the subject: a) reduced amount of nlrc5 mrna or protein; b) reduced activity of nlrc5 protein; c) a mutation that reduces the activity of nlrc5 protein; d) increased methylation of nlrc5 or a portion thereof; and e) reduced copy number of nlrc5.
The Texas A&m University System

Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

The present invention provides antibodies that bind to cd3 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human cd3 with high affinity and induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.

Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof

Novel activating receptors of the ig super-family expressed on human myeloid cells, called trem(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of trems, trem-1 and trem-2 are disclosed.
Novo Nordisk A/s

Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses

Epitopes derived from human papilloma virus and peptides having a size of about 22-45 amino acid residues comprising minimal t cell epitopes are disclosed. Also disclosed are clinically relevant approaches for immunizing subjects against (myco) bacterially and/or virally infected cells or tumor cells.
Academisch Ziekenhuis Leiden

Methods and compositions for enhancing immune response

Methods and compositions for enhancing the immune response to an irm compound by depositing within a localized tissue region an irm depot preparation that provides an extended residence time of active irm within the localized tissue region.. .
3m Innovative Properties Company

Compositions and methods for self-adjuvanting vaccines against microbes and tumors

The present invention is drawn to compositions and methods to enhance an immune response in order to prevent or treat infections or hyperproliferative diseases such as cancer. More particularly, the composition is an immunostimulatory intracellular signaling peptide fused directly or indirectly to a peptide that leads to multimerization into complexes of three or more units, where the intracellular signaling peptide must be present in a complex of three or more units in order to stimulate an immune response.
The Regents Of The University Of California

Antifugetactic agents for the treatment of cancers

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides fugetactic agents and methods for the use thereof in enhancing an immune response..
The General Hospital Corporation

Mhc-i restricted epitopes containing non-natural amino acid residues

The invention provides for the synthesis of more effective generators of a t-cell immune response by providing peptide derivatives that are mhc class i-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the c-terminus..
Purdue Pharma L.p.

Detection of an immune response

Provided herein are methods of detecting and/or monitoring the presence or severity of an immune disorder in a subject, including detecting a frequency of a th2a subset of cd4+ t cells in a biological sample of the subject. In some embodiments, the detecting includes: (a) detecting a frequency of cd4+ t cells in a biological sample of said subject; (b) detecting a frequency of a th2a subset of the cd4+ t cells in the biological sample; and (c) comparing the frequency of the th2a subset with the frequency of the cd4+ t cells..

Methods and compositions pertaining to human cerebral cavernous malformations

The disclosure is based on the discovery that aberrant immune responses are contributing to the pathogenicity of ccms in patients, and that blocking those responses treats the ccm. Described herein is a method for treating ccms in a patient in need thereof comprising administering a therapeutically effective amount of a b-cell immunomodulation therapy to the patient..

Modified virus-like particles of cmv

The present invention relates to virus-like particles of plant virus cucumber mosaic virus (cmv), and in particular to modified vlps of cmv comprising th cell epitopes, in particular universal th cell epitopes. Furthermore, these modified vlps serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified vlps.

Branched oligonucleotides

Provided herein are branched oligonucleotides exhibiting efficient and specific tissue distribution, cellular uptake, minimum immune response and off-target effects, without formulation.. .

Modulation of nkt cell activity with antigen-loaded cd1d molecules

The invention is directed to methods of modulating an immune response in an animal, comprising administering a composition comprising one or more soluble cd1d complexes, in particular non-specific soluble cd1d complexes. Soluble cd1d complexes comprise a soluble cd1d polypeptide, a β2-microglobulin polypeptide, and a ceramide-like glycolipid antigen bound to the cd1d antigen binding groove, and in certain embodiments, an immunogen.

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

The present description relates to t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. In particular, the present description relates to tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as igf2bp3-001 have the amino acid sequence of kiqeiltqv (seq id no:1).

Cartilage cells with a high regenerative potential and low immune response for use in cellular therapy

Cell-based therapies for cartilage repair and regeneration selectively using chondrocytes carrying a cd24 surface marker are disclosed. In particular, chondrocytes carrying the cd24 surface marker have a high regenerative potential and low responsiveness to inflammatory cues.

Compositions comprising ch848 envelopes and uses thereof

In certain aspects the invention provides immonogenic compositions comprising ch848 hiv-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.. .

Platform for the identification of tumor-associated cancer/testes antigens

Methods of identifying cancer/testes antigens (ctas) useful as cancer treatment targets are disclosed and claimed herein. The methods include identifying human sperm proteins to which patients diagnosed with solid or hematological malignancies have established a humoral immune response..
Kiromic Biopharma, Inc.

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18), and compositions comprising one or more additional therapeutic agents. Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.

Compositions and methods of use for augmented immune response and cancer therapy

The present invention provides antibody compositions, including, e.g., antibodies, engineered antibodies and antibody fragments that bind to a tumor necrosis factor receptor superfamily member (i.e., 18). Provided compositions are useful in enhancing cd4+ and cd8+ t cell responses, and in the treatment, amelioration and prevention of diseases that can be counteracted with an augmented immune response, e.g., cancers.
Novartis Ag

Glycoengineered binding protein compositions

Provided are glycoengineered populations of fc domain-containing binding proteins with a reduced anti-drug immune response (ada). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions..
Abbvie Inc.

Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria.
The University Of Chicago

Immunotherapy against melanoma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods of modulating immune system responses

Novel methods and uses for modulating immune responses are provided. The methods and uses involve the use of a tifa activator such heptose-1,7-5 bisphosphate or an analogue or derivative thereof.
The Governing Council Of The University Of Toronto

Vaccination of immunocompromised subjects

Disclosed herein are methods for enhancing immune responses to a vaccine in immunocompromised individuals, including those receiving a statin therapy. Related products are also provided..
Seqirus Uk Limited

Compositions and methods for increasing immunogenicity of glycoprotein vaccines

The present invention relates to the microbial immunogens engineered to bear α-gal epitope(s) for induction of potent humoral and cellular immune responses when administered to subjects having anti-gal antibodies. In one embodiment, the present invention provides compositions and methods for propagating influenza virus in human, ape, old world monkey or bird cells that have been engineered to express an α1,3galactosyltransferase (α 1,3gt) gene to produce virions bearing hemagglutinin molecules containing α-gal epitopes, to increase the immunogenicity of the influenza virus.
University Of Massachusetts

Recombinant modified vaccinia virus ankara (mva) filovirus vaccine

The present invention relates to an improved filovirus vaccine comprising a recombinant modified vaccinia virus ankara-based (mva-based) vaccine against filovirus infection and to related products, methods and uses. Specifically, the present invention relates to genetically engineered (recombinant) mva and fpv vectors comprising at least one heterologous nucleotide sequence encoding an antigenic determinant of a marburg virus (marv) or ebola virus glycoprotein.
Bavarian Nordic A/s

Attenuated mannheimia haemolytica strains

The present invention provides attenuated m haemolitica strains that elicit an immune response in animal against m haemolitica, compositions comprising said strains, methods of vaccination against m haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease..
Biotechnology Research And Development Corporation

Compositions and methods for immunizing against c. difficile

This disclosure relates to methods for eliciting an immune response against c. Difficile toxin a and toxin b in an adult human subject.
Sanofi Pasteur, Inc.

Universal donor checkpoint inhibitor silenced/gene edited cord blood killer cells

Disclosed are compositions of matters, cells, and treatment protocols useful for induction of anticancer responses in a patient suffering from cancer. In one embodiment the invention provides the use of nr2f6 silencing or gene editing in cord blood cells possessing anti-tumor activity in order to induce potentiated killer cells suitable for therapeutic use.
Regen Biopharma, Inc.

Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells

Described herein are compositions and techniques related to generation and therapeutic application of stem cell-derived exosomes. The inventors have discovered cardiosphere-derived cells (cdcs) and their secreted exosomes mediate such inflammatory processes, by, for example, shifting macrophages away from a proinflammatory m1 phenotype toward m2 healing phenotype.
Cedars-sinai Medical Center

Glycotargeting therapeutics

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.. .

Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases

The invention provides methods for the ex-vivo expansion of cd4+cd25+ tregs. The invention provides a method for producing ex vivo expanded tregs that may be used to inhibit unwanted human immune responses against self-antigens or allergens.

Prefusion rsv f proteins and their use

Disclosed are immunogens including a recombinant rsv f protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens.

New immunostimulatory compounds

The present invention relates to novel immunostimulatory molecules which are derived from the intestinal protozoan entamoeba histolytica. The compounds have been found to be useful for enhancing and/or inducing an immune response in a subject in need thereof.

Prolyl hydroxylase inhibitors

Disclosed herein are prolyl hydroxylase inhibitors that can stabilize hypoxia inducible factor-1 alpha (hif-1α), as well as hypoxia inducible factor-2 (hif-2). Also disclosed herein are pharmaceutical compositions comprising one or more of the disclosed compounds.

Single wall nanotube constructs and uses thereof

The present invention provides soluble single wall nanotube (swnt) constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble swnt via a dna or other oligomer platform attached to the swnt.

Frictional trans-epithelial tissue disruption collection apparatus and inducing an immune response

The invention relates to trans-epithelial frictionally abrasive tissue sampling devices for performing biopsies and methods of inducing an immune response against a pathogen, wherein epithelial cells containing the pathogen are disrupted with the frictionally abrasive tissue sampling device to introduce the pathogen into the bloodstream of a patient.. .

Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Novel peptides and combination of peptides for use in immunotherapy against nhl and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Synergistic compositions of immunostimulating reconstituted influenza virosomes with immunopotentiators and vaccines containing them

The present invention is directed to a preparation of an adjuvant system to achieve required level of humoral and cellular immune response against antigen of interest. The current invention provides an adjuvant system comprising an immunostimulating reconstituted influenza virosomes (irivs) and immunopotentiators.

Materials and methods for improving immune responses and skin and/or mucosal barrier functions

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype..

Compositions and methods for modulating an immune response

The disclosure relates to, among other things, agents that modulate the homophilic interaction between two cracc polypeptides, methods for making such agents, and therapeutic applications in which the agents are useful. For example, the agents described herein are useful for modulating an immune response in a mammal.
Board Of Trustee Of Michigan State University

Pichinde virus reverse genetics systems and methods of use

Provided herein are genetically engineered pichinde viruses that include three ambisense genomic segments. The first genomic segment includes a coding region encoding a z protein and a coding region encoding a l rdrp protein.
Regents Of The University Of Minnesota

Modulation of stimulatory and non-stimulatory myeloid cells

Provided herein are methods and compositions for enhancing an immune response and/or for the treatment of an immune-related condition in an individual, e.g., cancer, comprising killing, disabling, or depleting non-stimulatory myeloid cells using an antigen binding protein such as an antibody or antigen binding fragment thereof.. .
The Regents Of The University Of California

Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin

Provided herein are immunogenic compositions comprising a recombinant modified vaccinia virus ankara (mva) comprising a nucleic acid sequence encoding a flagellin, and a nucleic acid sequence encoding a heterologous disease-associated antigen, wherein the immunogenic composition induces increased t-cell and antibody mediated immune responses specific for the heterologous disease-associated antigen when administered to a subject, e.g. A human subject, and related methods and uses..
Bavarian Nordic A/s

Vlps containing ligands and methods related thereto

This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a tlr5 agonist on the exterior without an antigen..
Children's Healthcare Of Atlanta, Inc.

Means and methods for active cellular immunotherapy of cancer by using tumor cells killed by high hydrostatic pressure and dendritic cells

Disclosed are pharmaceutical compositions for inducing an immune response against tumor cells comprising tumor cells which are made apoptotic by treatment with high hydrostatic pressure and dendritic cells, and methods for producing such compositions.. .
Sotio A.s.

Priming of an immune response

The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.. .
University Of Copenhagen

Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against aml and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure

A monocomponent vaccine effective to moderate the clinical consequences of chages disease, capable of stimulating an immune response against the trans-sialidase virulence factor of the trypanosoma cruzi parasite. The vaccine active ingredient is an immunogenic component with a polynucleotide encoding one or more polypeptide(s) which includes a c-terminal region composed of at least two repetitive units of amino acids, with a polypeptide with trans-sialidase activity of trypanosoma cruzi fused to the c-terminal region.

Heartworm vaccine, methods and uses thereof

The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence.
Merial Inc.

Compositions and methods for treating and preventing inflammation

The present invention provides novel compounds compositions and methods for (i) treating or preventing inflammation; and (ii) preventing or reducing hyperactivation of innate immune response, by inhibiting nrp1-dependent cell-signaling. Also provided are compounds, composition, and methods of specifically inhibiting sema3a-mediated cell signaling..
Rsem, Limited Partnership

Cancer vaccine compositions and methods of use thereof

The present application describes compositions that include an epitope of a peptide that elicits an immune response in a subject following administration. The compositions described herein include nucleic acids.
University Of Washington

Immune system modulation for prophylaxis and treatment of diseases and disorders

The invention is directed to biological response modifiers (brm) which may contain one or more compounds, and to methods for enhancement of an immune system with brms of the invention including augmenting a specific immune response either prophylactically or for treatment, as an adjuvant or vaccine when coupled with a pathogenic antigen, and for boosting an immune system generally. The invention is also directed to the reduction of an unrestrained or improper inflammatory response and/or an immune response such as to treat or prevent autoimmune diseases and disorders, and associated symptoms.
Marpe Holdings, Llc

Combination therapy for inducing immune response to disease

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Compositions and methods for enhanced innate immunity

The disclosed compositions and methods relate to an immunogenic composition that, in certain aspects, comprise cationic liposomes; a mixture of toll like receptor 3 (tlr3) and toll like receptor 9 (tlr9) ligands; and a cellular adhesion agent, and methods of using such compositions. In certain aspects, disclosed compositions are administered to a mammal to induce a non-specific innate immune response at mucosal surfaces.
Colorado State University Research Foundation

Low, immune enhancing, dose mtor inhibitors and uses thereof

The present invention relates, in part, to compositions and methods for enhancement of an immune response by partial mtor inhibition, e.g., with low, immune enhancing, doses of an mtor inhibitor, such as rad001.. .
Novartis Institutes For Biomedical Research, Inc.

H3.3 ctl peptides and uses thereof

Peptides that generate an immune response to glioma-related h3.3 proteins and methods of their use are provided.. .
Regents Of The University Of California

Method of treatment using liposomally formulated reduced glutathione to cooperate with il-10 to modulate inflammatory response triggered in hiv+ and tb immune-compromised diabetic patients

In the setting of chronic infection with a pathogen, the immune system must adapt to the ongoing presence of inflammatory responses driven by the pathogen in order to control the replication of the infecting agent at an acceptable level while limiting immune-mediated damage (immunopathology) (1). A complex interaction is required to accomplish this using a balance of immune related cytokines to stimulate and control the immune response.
Western University Of Health Sciences

Immunomodulation using spores and pollen grains

The present invention includes compositions, methods of making and using the compositions for modulating the immune response in a subject by providing a vaccine composition having a pollen or spore disposed in a pharmaceutical carrier for delivery to a subject, wherein the pollen or spore comprises multiple pores that connect an outer surface of the pollen/spore to an inner cavity and one or more antigens disposed on the outer surface, in the inner cavity, in the multiple pores, or a combination thereof, wherein the one or more antigens modulate an immune responses in the subject.. .
Texas Tech University System

Antibodies and molecules derived therefrom that bind to steap-1 proteins

Antibodies and molecules derived therefrom that bind to novel steap-1 protein, and variants thereof, are described wherein steap-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i. Consequently, steap-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer.
Agensys, Inc.

Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for a tumor-associated antigen (taa) and at least one binding site for an antigen expressed on an effector t cell, nk cell, monocyte or neutrophil. The bispecific antibodies are of use for inducing an immune response against a taa-expressing tumor.
Ibc Pharmaceuticals, Inc.

Herpes simplex virus vaccine

Herpes simplex virus (hsv) antigens that elicit an hsv-specific immune response and can be used to treat or prevent hsv infection are provided. Nucleic acid sequences, polypeptides, vectors, and compositions, as well as methods to induce an immune response against hsv, treat or prevent hsv disease, induce a t cell response against hsv, and induce an antibody response against hsv also are provided..
Genvec, Inc.

Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of dengue virus infection

Dengue fever (df) and dengue hemorrhagic fever (dhr) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive t cell responses.
Emergex Vaccines Holdings Limited

Compositions and methods for the prevention and treatment of cancer

Conventional cancer immunotherapy falls short at efficiently expanding t cells that specifically target cancerous cells in numbers sufficient to significantly reduce the tumor size or cancerous cell number in vivo. To overcome this limitation, provided herein are nanoparticles coated with mhc class i and/or class ii molecules presenting tumor-specific antigens and co-stimulatory molecules and their use to expand antigen-specific anti-tumorigenic t cells to levels not achieved in current immunotherapeutic techniques.
Uti Limited Partnership

Treatment of cancer using tlr9 agonist with checkpoint inhibitors

The invention provides methods of inducing an immune response to cancer comprising co-administering to a cancer patient one or more tlr9 agonists and one or more checkpoint inhibitors. Preferably, the one or more tlr9 agonists are administered to the patient via intratumoral (i.t.) administration..
Idera Pharmaceuticals, Inc.

Combined enteropathogen recombinant construct

The inventive subject matter relates to a construct comprising antigens derived from multiple enterobacteria including campylobacter jejuni capsule polysaccharide polymer, enterotoxigenic escherichia coli recombinant polypeptide construct and lipopolysaccharide from shigella spp. The subject invention also relates to a method of inducing an immune response utilizing the inventive composition..
Koh Young Technology Inc.

Mass-spectral selection, and de-selection, of cancer patients for treatment with immune response generating therapies

A method and system for predicting in advance of treatment whether a cancer patient is likely, or not likely, to obtain benefit from administration of a yeast-based immune response generating therapy, which may be yeast-based immunotherapy for mutated ras-based cancer, alone or in combination with another anti-cancer therapy. The method uses mass spectrometry of a blood-derived patient sample and a computer configured as a classifier using a training set of class-labeled spectra from other cancer patients that either benefited or did not benefit from an immune response generating therapy alone or in combination with another anti-cancer therapy.
Globeimmune Inc.

Ompa in vaccine compositions and as diagnostic targets

Anaplasma marginale surface protein ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University

Compositions and methods for modulating immune responses

The present invention provides a newly identified b7 receptor, zb7r1 that functions as lymphocyte inhibitory receptor, which is a pd-1-like molecule and is expressed on t cells. The present invention also provides the discovery of zb7r1's ability to bind to cd155.
Zymogenetics, Inc.

Immunotherapy with binding agents

Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides.
Oncomed Pharmaceuticals, Inc.

Fviii peptides for immune tolerance induction and immunodiagnostics

The present invention is related to peptides that can be used to reduce the immune response against fviii or to induce tolerance to human fviii in patients with, e.g., hemophilia a. Furthermore, the peptides can be used for immunodiagnostic purposes to detect fviii-specific cd4+ t cells to monitor patients with hemophilia a during replacement therapy and during immune tolerance induction therapy..
Baxalta Gmbh

Transfected t-cells and t-cell receptors for use in immunotherapy against cancers

Disclosed are t-cell receptors (tcrs) binding to tumor-associated antigens (taas) for targeting cancer cells, t-cells expressing same, methods for producing same, and methods for treating cancers using same. Disclosed are tcrs and their variants that bind to hla class i or ii molecules with a peptide, such as mag-003 have the amino acid sequence of kvlehvvrv (seq id no:1).
Immatics Biotechnologies Gmbh

Compositions including beta-glucans and use

The invention generally relates to soluble beta-glucan compositions and method of using such compositions. In one aspect, an adjuvant for a pharmaceutical composition is described which includes a soluble beta-glucan and a tlr agonist, each in an amount that, in combination with the other, is effective to increase a subject's immune response to an antigen.
Biothera, Inc.

Mutant porcine epizootic diarrhea virus for use in a vaccine

The invention relates to a mutant porcine epizootic diarrhea virus (pedvdn), to methods of producing said pedvdn, and to compositions comprising the pedvdn. The invention further relates to methods of stimulating an immune response in a pig comprising administering the pedvdn, to vaccines comprising the pedvdn, and to methods for preventing or ameliorating porcine epizootic diarrhoea in a pig..
Universiteit Utrecht Holding B.v.

Peptides and combination of peptides for use in immunotherapy against cancers

The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods of identifying antigens for vaccines

The methods, processes, and systems described herein include identifying an epitope of a peptide that may elicit an immune response in a subject. Often the methods, systems and processes may include designing and producing a composition comprising an epitope of a peptide identified using the methods or processes described herein..
University Of Washington Through Its Center For Commercialization

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Ds Pharma Animal Health Co., Ltd.

. .

Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration

A method for diagnosing or treating a mammalian subject having, or at risk of developing cancer, comprising: generating a circulating anti-cancer cd4+ th1 response from antigen presenting cells or their precursors and cd4+ t-cells from a sample of said subject's blood which causes secretion of interferon-gamma (“ifn-γ”); and detecting said anti-cancer cd4+ th1 response to determine if said response is depressed. A method for restoring her2-specific cd4+ th1 immune response in a her2-positive breast cancer patient in need thereof, comprising: administering to said patient a therapeutically effective amount of a dendritic cell (“dc”) vaccine comprising autologous dcs pulsed with her2-derived mhc class ii binding peptides (“dc vaccination”) to elevate said patient's anti-her2 cd4+ th1 response, and measuring said anti-her2 th1 response of said patient pre- and post-dc vaccination to determine the amount of increase in said response..
The Trustees Of The University Of Pennsylvania

Antigen-binding fusion proteins with modified hsp70 domains

The invention relates to fusion proteins comprising an antigen binding domain fused with a modified heat shock 70 protein. The invention further relates to methods of using the fusion proteins to induce an immune response to antigens and to treat diseases associated with antigens..
Aperisys, Inc.

Gitr antibodies, methods, and uses

Provided herein are antibodies that specifically bind to gitr. Also described are related polynucleotides capable of encoding the provided gitr-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments.
Janssen Biotech, Inc.

T cell-redirected antigen-binding molecule for cells having immunosuppression function

It was discovered that antigen-binding molecules comprising (i) a domain that binds to a molecule expressed on the surface of cells having immune response-suppressing functions, and (ii) a t cell receptor complex-binding domain exhibit more superior antitumor effects than conventional antigen-binding molecules by crosslinking t cells with cells having immune response-suppressing functions, and damaging the cells having immune response-suppressing functions.. .
Osaka University

Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.
Axon Neuroscience Se

Uterine cancer treatments

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Broad spectrum conjugate vaccine to prevent klebsiella pneumoniae and pseudomonas aeruginosa infections

The present invention is drawn to conjugates and vaccine compositions comprising a pseudomonas flagellin or an antigenic fragment or derivative thereof linked to one or more klebsiella surface polysaccharide antigens, such as klebsiella pneumoniae o5 polysaccharide from serovars o1, o2a, o2a,c, o3, o4, o5, o7, o8 and 012. The present invention also provides serovar reagent strains to produce the conjugates and vaccine compositions and methods of inducing an immune response with the conjugates and vaccine compositions..

Skin penetrating peptides (spps) and methods of use therefor

The present disclosure provides peptides and peptide compositions, optionally in the from of a vaccine, which facilitate the delivery of an active agent or an active agent carrier wherein the compositions are capable of penetrating the stratum corneum (sc) and/or the cellular membranes of viable cells. Also provided are methods of employing the peptides and peptide compositions to deliver active agents; treat diseases or disorders; and inducing immune responses..
Ctx Technology Inc.

Antagonism of the vip signaling pathway

Inhibition of the vip signaling pathway with vip antagonist is contemplated. In certain embodiments, the disclosure relates to methods of enhancing the immune response to a cell therapy comprising administering a vip antagonist to a subject in combination with a cell.
Emory University

Versikine for inducing and potentiating an immune response

Disclosed are methods, kits, polypeptides, and pharmaceutical compositions for inducing an immune response in a subject, which may include a t-cell mediated immune response. The methods comprise administering to the subject, or to explanted cells of the subject, a pharmaceutical composition comprising an effective amount of versikine or a variant of versikine that induces the t-cell mediated immune response.
Wisconsin Alumni Research Foundation

Novel mucosal vaccination approach for herpes simplex virus type-2

The invention provides methods and kits for immunizing animals (e.g. Mammals) against viral antigens, including herpes-simplex virus type 2.
Biomedical Research Models, Inc.

Compositions and methods to treat aids

Polyvalent, primary isolate nucleic acid compositions for inducing an immune response against hiv are disclosed. The compositions and methods described herein are for the use of a nucleic acid composition that encodes one or more different hiv envelope glycoproteins.
University Of Massachusetts

Methods of treating graft versus host disease (gvhd) or epidermolysis bullosa (eb)

We describe the use of exosome such as mesenchymal stem cell exosomes in a method of promoting, restoring or enhancing homeostasis in an individual suffering from graft versus host disease (gvhd) or epidermolysis bullosa (eb). The homeostasis may comprise immune homeostasis such as maintenance of an immune response.
Agency For Science, Technology And Research

Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations

The disclosure provides among others a combination of a vaccine and a cd94/nkg2a and/or a cd94/nkg2b binding antibody for use in the treatment of a subject in need thereof, wherein said vaccine comprises an immunogen for eliciting an immune response against an antigen or a nucleic acid molecule encoding said immunogen.. .
Academisch Ziekenhuis Leiden H.o.d.n. Lumc

Anti-pd-l1 antibodies and uses thereof

The present application relates to anti-pd-l1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.. .
Merck Patent Gmbh

Anti-pd-l1 antibodies and uses thereof

The present application relates to anti-pd-l1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.. .
Merck Patent Gmbh

Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compound and method

The present invention provides a method of expressing an antigenic molecule or a part thereof on the surface of a cell using a photochemical internalisation method in which a cytokine, preferably gm-csf, is used to enhance the method. The method may be used to stimulate an immune response and for various therapeutic or prophylactic methods.
Pci Biotech As

Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid molecule and as a preferably non-toxic and non-immunogenic polymeric carrier disulfide-crosslinked cationic components for use as an immunostimulating agent or as an adjuvant, wherein the polymeric carrier cargo complex is administered in combination with at least one second nucleic acid molecule, which encodes a protein or peptide. The inventive polymeric carrier cargo complex administered in combination with the second nucleic acid molecule allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an innate and/or adaptive immune response, preferably dependent on the nucleic acid to be transported as a cargo and on the second nucleic acid molecule.
Curevac Ag

Organic vaccination an alternative method to traditional preventative vaccination

The disclosed method provides an alternative approach of preventative vaccination which consists primarily of extracting and purifying monocytes, naive t and b lymphocytes from a patient and educating said lymphocytes against a pathogen in vitro until a population of antigen-specific memory lymphocytes are created with a memory against an infectious agent. Said memory lymphocytes are administered to a subject in a solution which consist primarily of blood plasma derived from said subject.

Compounds against ralstonia pickettii for use in the treatment of insulin resistance, and diagnosis of insulin resistance

Compounds disclosed herein are effective against ralstonia pickettii for treating or preventing insulin resistance, obesity or type ii diabetes of a subject, and include an antibiotic effective against ralstonia pickettii, an immunogenic compound producing a protective immune response, or an antibody which specifically binds to ralstonia pickettii or a fragment thereof. In vitro methods for diagnosis or prediction of insulin resistance, obesity or type ii diabetes include determining the presence of ralstonia pickettii or of an antibody which specifically binds to ralstonia pickettii in a test sample.
Wageningen Universiteit

Three-component-multistage malaria vaccine

The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Frauhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Protein-chaperoned t-cell vaccines

Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a “chaperone-antigen” that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone.
Massachusetts Institute Of Technology

Autologous implantation of chimeric murine-human tumors, generated in pdx mice, for ativation of an anti-tumor immune response in the donor patient

Here, we present a specific and novel method for treating cancer by eliciting an anti-tumor immune response in cancer patients. Specifically, this technique involves subcutaneous “auto-im-transplantation” of chimeric murine-human tumors, created in pdx mice, back to the original donor patients.

Immunomodulating compositions and methods of use thereof

This invention is directed to β-1-6-glucans, compositions and devices comprising the same, and methods of use thereof in modulating immune responses. The β-1-6-glucans of certain embodiments of the invention are enriched for o-acetylated groups and/or conjugated to a solid support or linked to a targeting moiety..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Progenitor cells, preparation thereof and uses thereof

The present application provides progenitor cells and a preparing method thereof. The preparing method comprises obtaining a tissue sample containing myometrium from uterus, treating the tissue sample with collagenase, and culturing the treated tissue sample to obtain the progenitor cells, wherein the progenitor cell is multipotent and immunomodulatory.
National Health Research Institutes

Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases

The present invention pertains to the field of immunoterapy. More specifically, the present invention provides a method for differentiating myeloid-derived suppressor cells (mdsc) into non suppressive cells, by administering a compound blocking the interaction between sirpa and cd47 to a patient in need thereof in order to reduce mdsc-induced immunodepression and consequently allow appropriate immune responses in cancers, infectious diseases, vaccination, trauma, autoimmune diseases, chronic inflammatory diseases and transplantation..
Ose Immunotherapeutics

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

An improved process of conjugation and novel synthetic oligosaccharide- protein conjugates obtained thereof

The present invention relates to an improved process of conjugation to obtain synthetic oligosaccharide-protein (os-pr) conjugates. The process of synthetic os-pr conjugation is a rapid process providing oligosaccharide-protein conjugates which are highly immunogenic and elicit specific and homogenous immune responses.
Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd.

Novel immunostimulatory method

This invention relates to a method for treating or preventing a disease by raising an innate immune response in a subject, the method comprising administering to the subject an effective amount of a composition comprising a tlr2 moiety in solution, wherein the tlr2 moiety comprises a tlr2 agonist and wherein the disease is not treated or prevented by a humoral or cellular immune response directed against the tlr2 moiety.. .
Innavac Pty Ltd

Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

The present invention provides methods and compositions for the stimulation of immune responses and for treating or preventing allergic disease and responses and inflammatory disease and responses. In particular, the present invention provides nanoemulsion compositions and methods of using the same for the induction of immune responses that prevent or treat allergic disease by reducing allergic response.
The Regents Of The University Of Michigan

Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof

A vaccine comprising an immunologically effective amount of recombinant modified vaccinia ankara (rmva) virus which is genetically stable after serial passage and produced by a) constructing a transfer plasmid vector comprising a modified h5 (mh5) promoter operably linked to a dna sequence encoding a heterologous foreign protein antigen, wherein the expression of said dna sequence is under the control of the mh5 promoter; b) generating rmva virus by transfecting one or more plasmid vectors obtained from step a) into wild type mva virus; c) identifying rmva virus expressing one or more heterologous foreign protein antigens using one or more selection methods for serial passage; d) conducting serial passage; e) expanding an rmva virus strain identified by step d); and f) purifying the rmva viruses from step e) to form the vaccine. One embodiment is directed to a fusion cytomegalovirus (cmv) protein antigen comprising a nucleotide sequence encoding two or more antigenic portions of immediate-early gene-1 or immediate-early gene-2 (iefusion), wherein the antigenic portions elicit an immune response when expressed by a vaccine..
City Of Hope

T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

The present invention concerns methods and compositions for treatment of hiv infection using a t20 expression vector, such as that shown in seq id no:1 or seq id no:3. The t20 expression vector may be used in a variety of therapeutic applications, such as ex vivo transfection of dendritic cells to induce a host immune response to hiv, localized transfection in vivo in a gene therapy approach to provide longer term delivery of t20, or in vitro production of t20 peptide.
Immunomedics, Inc.

Method of quickly producing antibodies against avian influenza and maintain antibody titer of duck

The present invention provides a method for enabling ducklings to quickly produce anti-avian influenza antibodies and maintain antibody titer, including: step 1) the first immunization is performed on ducklings at the age of 5 to 15 days: each duckling is inoculated with an avian influenza inactivated antigen in an abdomen, and simultaneously intramuscularly or subcutaneously immunized with an avian influenza inactivated oil-emulsion vaccine. In the method, through the double effects of intraperitoneal inoculation with the inactivated antigen and intramuscular or subcutaneous injection with the inactivated oil-emulsion vaccine on the ducklings, the ducklings can quickly produce an immune response so as to quickly produce the anti-avian influenza antibodies; and the immune dead time of the ducklings immunized with the avian influenza inactivated vaccine can be effectively reduced by more than 7 days..
South China Agricultural University

Attenuated mannheimia haemolytica vaccines and methods of making and use

The present invention provides attenuated m. Haemolitica strains that elicit an immune response in animal against m.
Merial Inc.

Staphylococcus aureus materials and methods

The disclosure generally relates to the field of prevention and treatment of staphylococcus aureus infections. In particular, the disclosure relates to immunogens comprising staphylococcus aureus antigens and methods for generating immune responses to immunogens, and to antibody products specific for the staphylococcus aureus epitopes and methods for treating staphylococcus aureus infection with the antibody products..
The Regents Of The University Of Michigan

Immunogenic polypeptide cocktail for the treatment of medullary thyroid carcinoma

Disclosed are immunogenic compositions that include one or more polypeptides that, when administered to a subject with adjuvant, elicit an immune response against medullary thyroid cancer. Disclosed are methods of eliciting an immune response and/or treating cancer, such as medullary thyroid carcinoma or other thyroid carcinomas..

Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof

Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.. .
City Of Hope

Compositions and methods for treating b cell mediated autoimmune disorders

Provided herein are methods, kits, compositions and uses related to the treatment of a b cell mediated autoimmune disorder with a t cell vaccine comprising a therapeutically effective amount of t cells autologous to the patient and that react to an autoantigen or specific epitope(s) thereof associated with the b cell mediated autoimmune disorder, wherein the treatment is provided to a patient in need thereof having suppressed b cell immune responses.. .
Opexa Therapeutics, Inc.

Innate immune modulating molecule complex for the activation of the innate immune system of aquatic animals and methods therefor

A method for application of an innate immune modulating molecule complex to activate the innate immune system of aquatic animals includes selecting a recombinant dna with characteristics configured for activating aquatic animal macrophages, such as by inducing an innate immune response in the animal. The method for application of an innate immune modulating molecule complex also includes selecting an adjuvant with characteristics favorable for activating aquatic animal macrophages and causing the release of cytokines.
Perkins Biosystems, Llc

Antiviral treatment with low immunogenicity

Compositions and methods are disclosed for reducing toxicity and immunogenicity of nucleases, especially when in use for cutting viral nucleic acids in host cells. Different nucleases that cut the same target are delivered at different times to avoid an immune response that interferes with a therapeutic effect of the nucleases..
Agenovir Corporation

Antigen specific mrna cellular cancer vaccines

Disclosed are antigen specific cancer vaccines in which immunogenic epitopes are produced intracellularly by administration of modified mrna encoding said immunogenic epitopes. In one embodiment of the invention, said modified mrna encodes peptides derived from the protein survivin.
Regen Biopharma, Inc

Compositions comprising dihydroquercetin for use in methods for treating the effects associated with skin inflammatory disorders

A method of using a composition including dihydroquercetin, as well as optionally α-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described..
Bionoox Suisse Sa

Method and kit for detection of mycobacteria

A method of determining whether an individual is infected with mycobacteria. The method comprising the steps of (a) providing a system which comprises at least two different mycolic-acid derived antigens; (b) introducing a sample obtained from the individual into the system and into contact with each of the at least two different mycolic-acid derived antigens; and (c) detecting the presence or absence of the binding of a biomarker in the sample with each antigen in the system.
Diagnostig Ltd

Actrii antagonists for use in increasing immune activity

Disclosed herein are actrii antagonists and methods for increasing immune responses and/or activity in patients in need thereof including, for example, cancer patients. In some embodiments, the disclosure relates to methods for treating cancer and/or tumors in a patient comprising administration of an actrii antagonists and a pd1-pdl1 antagonist..
Acceleron Pharma Inc.

Human alpha-folate receptor chimeric antigen receptor

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified t cell having α-folate receptor (frα) binding domain and cd27 costimulatory domain to treat ovarian cancer.
The Trustees Of The University Of Pennsylvania

Compositions and methods for modulating t-cell mediated immune response

The present disclosure relates to compositions and methods for modulating t-cell mediated immune response in a subject in need thereof. The method includes administering to the subject an effective amount of a cd112r protein, a fusion polypeptide, a complex including cd112r and a second protein, or an anti-cd112r antibody of the present disclosure..
The Regents Of The University Of Colorado

Compositions and methods related to neurological disorders

The present technology relates to compositions comprising inulin particles for use in the enhancement of immune responses to neuronal self-antigens for treating or preventing neurodegenerative diseases, in a subject. Also provided are pharmaceutically acceptable compositions comprising: particles of inulin; a substance comprising one or more pathogen-associated molecular patterns (pamps); and a neuronal self-antigen fused to carrier, and methods and uses of the composition for inducing or modulating an immune response in a subject, such as modulating an immune response to a neuronal self-antigen as a vaccine.
Vaxine Pty Ltd

Antiviral vaccines with improved cellular immunogenicity

The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects..
Los Alamos National Security, Llc

Methods for enhancing efficacy of a vaccine by administering an il-4r antagonist

The present invention provides methods for enhancing the efficacy and/or safety of a vaccine. In certain embodiments, the invention provides methods to increase or potentiate the immune response to a vaccine in a subject in need thereof.
Regeneron Pharmaceuticals, Inc.

Vaccines against streptococcus pneumoniae serotype 8

The present invention relates to synthetic saccharides of general formula (i) that are related to streptococcus pneumoniae serotype 8 capsular polysaccharide, conjugates thereof and the use of said saccharides and conjugates for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide structures of general formula (i) are useful as marker in immunological assays for detection of antibodies against streptococcus pneumoniae bacteria..
Max-planck-gesellschaft Zur FÖrderung Der Wissenschaften E.v.

Vaccine directed to induction of immune response to protein and glycolipid antigens of bacterial cells through interaction of cd40l/cd40 receptor axis with complex of glycolipid/cd1d receptor in nkt cells and in dendritic cells

A combination of components to promote an innate and adaptive immune response comprising of a taa/ecdcd40l vaccine and a complex between the cd1d receptor and an alpha galactosyl ceramide like glycolipid (agclgl), to activate nkt cells and activate the cd40 receptor on the dcs and increase the level of the adaptive immune response induced by the taa/ecdcd40l vaccine to the taa. The result and advantage of using both the taa/ecdcd40l vaccine and the α-galactosylceramide-cd1d complex (or a related bacterial or other antigen related to α-galactosylceramide) to stimulate the immune response through the cd40l/cd40 axis on dendritic cells, is that the magnitude of the stimulation is robust and increased significantly more than additive—i.e.
Microvax,llc

Combination immunotherapy approach for treatment of cancer

Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response.
Stemimmune, Incorporated

Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

The invention relates to prophylaxis and therapy of cancer. In particular there is provided a protein tryptophan2,3-di-oxygenase (tdo) or peptide fragments here of that are capable of eliciting anti-cancer immune responses.
Herlev Hospital

Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells

A genetically modified mesenchymal stem cell (msc) and medical use thereof in the treatment of tumors, the msc including one or more exogenous nucleic acid molecule(s), wherein the exogenous nucleic acid molecule(s) include a region encoding one or more immune response-stimulating or immune response-modulating cytokine(s) operably linked to a promoter or promoter/enhancer combination. The invention encompasses the use of the cells in modulating the tumor microenvironment in order to attract immune effector cells and facilitate their activation and/or adoption of a memory phenotype.
Apceth Gmbh & Co. Kg

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Method for inducing a sustained immune response

A method for inducing a sustained immune response in humans or animal patient suffering from human immunodeficiency virus (hiv) acquired immune deficiency syndrome (aids, autoimmune disease, cancer, inflammation, and neurodegenerative diseases comprises daily administration to such patients a single oral tablet, rapidly dissolving film, capsule, liquid or cream dose of an immediate release naltrexone composition comprising between about 0.01 to about 10 mg of naltrexone. In order to provide a benefit the naltrexone must be an immediate release composition comprising between about 0.01 and about 10 mg of naltrexone.
Immune Therapeutics Inc.

Markers of immune response

The present invention concerns methods for determining if a dendritic cell is a type 2 dendritic cell or a tolerogenic dendritic cell, methods for determining if a patient undergoing immunotherapy, and/or who has been administered with a vaccine, is developing an immune response oriented either towards a regulatory t cell response or towards an effector type 2 cell response, and methods of determining response to immunotherapy.. .
Stallergenes

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.
Idera Pharmaceuticals, Inc.

Antibody therapeutics that bind ctla4

There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Virus like particle comprising pd-1 antigen or pd-1 ligand antigen

The present invention provides a virus like particle comprising a virus structural protein and an antigen derived from pd-1 or a ligand of pd-1, and a composition or kit comprising thereof, its use in immune response etc.. .
Vlp Therapeutics, Llc

Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use

Various methods and compositions are provided which can be employed to modulate the immune system. Compositions include a fusion protein comprising: (a) a first polypeptide comprising interleukin-2 (il-2) or a functional variant or fragment thereof; and (b) a second polypeptide, fused in frame to the first polypeptide, wherein the second polypeptide comprises an extracellular domain of interleukin-2 receptor alpha (il-2rα) or a functional variant or fragment thereof, and wherein the fusion protein has il-2 activity.
University Of Miami

Recombinant hiv-1 envelope proteins and their use

Hiv-1 env ectodomain trimers stabilized in a prefusion mature closed conformation and methods of their use and production are disclosed. In several embodiments, the hiv-1 env ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to hiv-1 in a subject.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Vaccines having an antigen and interleukin-21 as an adjuvant

Disclosed herein is a vaccine comprising an antigen and il-21. Also disclosed herein are methods for increasing an immune response in a subject.
The Trustees Of The University Of Pennsylvania

Vaccine in the form of a recombinant sero type 9 avian adenovirus vector

The vector of this vaccine is stable for industrial scale production. Likewise, even when administering this vaccine in combination with a vaccine against marek's disease, both vaccines produce an adequate immune response which is not affected by interference between each other.

Novel antigen for use in malaria

The present invention provides polypeptides useful as antigens expressed at the pre-erythrocytic stage of the malaria parasite. The antigens can be utilized to induce an immune response and sterile protection against malaria in a mammal by administering the antigens in vaccine formulations or expressing the antigens in dna or other recombinant protein expression systems delivered as a vaccine formulation..
Camris International, Inc.

Multi-indication mrna cancer immunotherapy

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.

Treatment of inflammatory and dysimmune response

A drug and, more particularly, to a drug for treating inflammatory and dysimmune response. The present invention also relates to a drug for treating graft-versus-host disease.
Chu De Dijon

Disease therapy by inducing immune response to trop-2 expressing cells

The present invention concerns compositions and methods of use of bispecific antibodies comprising at least one binding site for trop-2 (egp-1) and at least one binding site for cd3. The bispecific antibodies are of use for inducing an immune response against a trop-2 expressing tumor, such as carcinoma of the esophagus, pancreas, lung, stomach, colon, rectum, urinary bladder, breast, ovary, uterus, kidney or prostate.
Ibc Pharmaceuticals, Inc.

Method for in vivo expansion of t regulatory cells

Compositions specific for tnf-receptor superfamily member 25 (tnfrsf25, dr3) modulate the immune response by regulating t regulatory cells.. .
University Of Miami

Antibody therapeutics that bind cd137

There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

An anti-cd45rc antibody for use as drug

The invention relates to an isolated anti-cd45rc antibody for use in preventing or treating transplant rejection, autoimmune diseases, unwanted immune responses against proteins expressed in the course of gene therapy and/or therapeutic proteins, allergy as well as lymphoma or cancer which are associated with cd45rc+ cells. The invention relates to an isolated anti-cd45rc antibody for use in expanding and/or potentiating regulatory t cells..
UniversitÉ De Nantes

Methods of modulating an immune response

The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to a filovirus (e.g., marburg virus (marv)), including antibodies that cross-react with at least two filoviruses. Such antibodies are useful for the prevention and treatment of filovirus infection.

Adenocarcinoma antigenic determinants and methods

Adenocarcinoma antigenic determinants, methods for their production and use, and broadly-specific human monoclonal antibodies reactive to the epitopes. These epitopes, which can be physically recapitulated, are conserved across a range of adenocarcinomas and are capable of eliciting an immune response in humans..
Vaccinogen, Inc.

Vaccine adjuvant compositions

Embodiments described herein relate to combinatorial compositions and uses thereof, for example, as vaccine adjuvant compositions, for enhancing immune response, for inducing differentiation of nave t cells to differentiate into ifn-γ-producing t cells, and for preventing and treating infections. The combinatorial composition comprises tlr and clr agonists.
Children's Medical Center Corporation

Therapeutic compositiojns and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2)

Disclosed are therapeutic compositions and methods for inducing an immune response to herpes simplex virus type 2 (hsv-2). More particularly, the invention relates to a method for inducing an immune response in a subject by introducing and expressing an hsv gd2-encoding dna vaccine..
Admedus Vaccines Pty Ltd

Recombinant bacterium and methods of antigen and nucleic acid delivery

The present invention provides a recombinant bacterium and methods of using the recombinant bacterium to induce an immune response.. .
The Arizona Board Of Regents For And On Behalf Of Arizona State University

Carrier molecule for antigens

The invention provides a conjugate comprising an antigen and a carrier molecule, wherein the carrier molecule comprises a bp-2a antigen and a spb1 antigen. Bp-2a and spb1 are streptococcus agalactiae antigens.
Glaxosmithkline Biologicals Sa

Cancer therapy using a vaccine in combination with a cell-based immunotherapeutic agent

A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel.
Xeme Biopharma Inc.

Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a delivery system

A therapeutic vaccine and a method of cancer treatment by inducing humoral and cellular immune responses against malignant cells is provided. The vaccine comprises a delivery system that incorporates at least one peptide whose sequence encompasses a genetic mutation associated with a malignancy (neoantigen), at least one immunostimulant, and at least one type of lipid molecule..
Xeme Biopharma Inc.

Cdca1 epitope peptides for th1 cells and vaccines containing the same

Isolated cdca1-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Materials and methods for improving immune responses and skin and/or mucosal barrier functions

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype..
Quorum Innovations, Llc

Discovery of regulatory t cells programmed to suppress an immune response

A method to treat an autoimmune disease is provided. The method involves administration of interleukin-15 receptor (il-15r) agonists in an amount effective to ameliorate a symptom of the autoimmune disease.
Dana-farber Cancer Institute, Inc.

Malaria antigen screening method

The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (apcs) in vitro or to an animal in vivo.
United States Of America As Represented By The Secretary Of The Navy

Expression system for modulating an immune response

The present invention discloses methods and compositions for modulating the quality of an immune response to a target antigen in a mammal, which response results from the expression of a polynucleotide that encodes at least a portion of the target antigen, wherein the quality is modulated by replacing at least one codon of the polynucleotide with a synonymous codon that has a higher or lower preference of usage by the mammal to confer the immune response than the codon it replaces.. .
Admedus Vaccines Pty Ltd.

Compositions and methods related to antibodies to staphylococcal protein a

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria.
The University Of Chicago

Innate immune system modification for anticancer therapy

The present invention relates to the discovery of a role of the nuclear receptor retinoid-related orphan receptor gamma (rorgamma) in tumor suppression. The introduction and expression of rorgamma result in genes activation within innate immune cells that trigger recognition and suppression of tumor cells.
Yale University

Messenger rna nanoparticles and preparation method therefor

Disclosed are nanoparticles that are introduced into cells and express a specific protein and a manufacturing method thereof. More particularly, the present invention relates to mrna nanoparticles, which increase the expression of a specific protein capable of stimulating the cellular immune system to induce cellular immune responses and are thus applicable to treat a variety of diseases, do not require passage across the nuclear envelope because a desired gene is delivered not as plasmid dna itself but in the form of mrna, thus improving the efficiency of protein expression, and the nanoparticles are generated through a one-step process with a relatively small amount of plasmid dna via rolling circle transcription (rct), thereby providing a simple and economical process for gene delivery.
University Of Seoul Industry Cooperation Foundation

Vaccine pharmaceutical composition for transdermal administration

The present invention provides a vaccine pharmaceutical composition for transdermal administration which is safe, usable as a prophylactic or therapeutic agent for cancer or infectious diseases, and capable of safely and effectively inducing a systemic immune response. It can be administered to a human or animal skin, the vaccine pharmaceutical composition including: a lipopolysaccharide or its salt derived from at least one gram-negative bacterium such as serratia, lelercia, rahnella, acidicaldus, acidiphilium, acidisphaera, acidocella, acidomonas, asaia, belnapia, craurococcus, gluconacetobacter, gluconobacter, kozakia, leahibacter, muricoccus, neoasaia, oleomonas, paracraurococcus, rhodopila, roseococcus, rubritepida, saccharibacter, stella, swaminathania, teichococcus, zavarzinia, pseudomonas, achromobacter, bacillus, methanoculleus, methanosarcina, clostridium, micrococcus, flavobacterium, pantoea, acetobacter, zymomonas, xanthomonas, and enterobacter, as an immunostimulant; and at least one antigen, the vaccine pharmaceutical composition having a mass ratio between the immunostimulant and the antigen, the total mass of the immunostimulant/the total mass of the antigen, of 0.002 to 500..
Nitto Denko Corporation

Vaccine for treatment and prevention of herpes simplex virus infection

The present invention relates to methods and compositions for the prevention and treatment of herpes virus infections. The invention provides antigenic peptides, and pharmaceutical compositions comprising complexes of antigenic peptides and adjuvants that can activate an immune response against herpes viruses.
Agenus Inc.

Compositions and methods for transient immune response modulation during vaccination

In certain aspects the invention provides a selection of hiv-1 envelopes suitable for use as immunogens, and methods of using these immunogens to induce neutralizing antibodies. In certain embodiments, the immunogens are designed to trimerize.
Duke University

Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof

The present invention relates to the preparation and use in primates of whole organismvaccines in which the mep pathway is disrupted such that synthesis of hmbpp by the bacterial cells is substantially blocked. The data provided demonstrates that, when bacteria or other vaccine vectors that comprise an active mep pathway are used in vaccine methods, the γδ t cell response dominates, potentially clearing the vaccine strain via γδ t cell-mediated killing of vector infected antigen presenting cells and reducing its utility as a stimulator of a productive adaptive immune response, specifically priming or boosting of cd4+ and cd8+ αβ t cell responses, specific for listerial-encoded antigens.
Providence Health & Services-oregon D/b/a Providence Portland Medical Center

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Inoculation by applying nanosecond pulsed electric fields to a biopsy and reintroducing the treated biopsy to the subject

A subject is inoculated from a disease by exposing a biopsy of a tumor or other abnormal growth to a nanosecond pulsed electric field (nspef). A sufficient treatment can be confirmed by detecting calreticulin on the tumor cell membranes, which indicates apoptosis occurring in the tumor cells.
Pulse Biosciences, Inc.

Methods and therapeutic combinations for treating tumors

Methods and therapeutic combinations useful for increasing cell-mediated anti-tumor responses are described. The methods include administering to a subject a therapeutically effective amount of an immune response modifier compound and a therapeutically effective amount of one or more immune checkpoint inhibitor compounds..
Board Of Regents, The University Of Texas System

Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome

The present invention relates to the field of clostridium difficile infections. Methods of diagnosing, treating and preventing clostridium difficile-associated disease and recurrent cdad are disclosed herein..
Assistance Publique - Hopitaux De Paris

Use of pdl1 expressing cells to convert t cells into regulatory t cells

The present invention provides methods and compositions for converting a t cell into a cell that exhibits at least one regulatory t cell phenotype. The converted t cell is generated by contacting a t cell with a cell that is modified to comprise an agent capable of activating pd1 signaling in a t cell.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Carbon nanotube compositions and methods of use thereof

Carbon nanotube (cnt)-based compositions for activating cellular immune responses are provided. The cnts function as high surface area scaffolds for the attachment of t cell ligands and/or antigens.
Yale University

Monovalent anti-cd3 adjuvants

This document provides methods and materials related to using monovalent anti-cd3 antibodies (e.g., monovalent anti-cd3 fab fragments) as adjuvants to increase the immune response produced against an antigen (e.g., a tumor associated antigen). For example, vaccine compositions containing monovalent anti-cd3γε fab fragments in combination with tumor associated antigens (e.g., tumor associated antigens having little or no immunogenicity in the absence of monovalent anti-cd3γε fab fragments) alone or in combination with adjuvants for signals two and/or three required for full activation of t cell immune function, as well as methods and materials for using monovalent anti-cd3γε fab fragments to increase the immune response produced against an antigen (e.g., a tumor associated antigen) within a mammal (e.g., a human) are provided..
Mayo Foundation For Medical Education And Research

A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

This invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1d or aa are also provided..
The University Of British Columbia

Activation of innate immunity for enhanced nuclear reprogramming of somatic cells with mrna

The nuclear reprogramming of somatic cells with mrna encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of pkr, of toll-like receptors, e.g.
The Board Of Trustees Of The Leland Stanford Junior University

Antagonistic peptides

The present invention relates to a compositions and methods for treating and/or preventing neurologic disorders such as alzheimer's disease and disorders associated with an increase of the th2 immune response such as allergic inflammation.. .
Deakin University

Vaccine delivery method

The present invention includes a composition including as one component a slurry matrix that is a liquid at room temperature and a gel at physiological ph, physiological salt concentrations and/or physiological temperatures and as a second component one or more antigens. Also include are methods of inducing an immune response in a subject and vaccinating a subject by administering such compositions..
University Of Georgia Research Foundation, Inc.

Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof

The present invention relates to an immunostimulatory composition comprising a) an adjuvant component, comprising or consisting of at least one (m)rna, complexed with a cationic or polycationic compound, and b) at least one free mrna, encoding at least one therapeutically active protein, antigen, allergen and/or antibody, wherein the immunostimulatory composition is capable to elicit or enhance an innate and optionally an adaptive immune response in a mammal. The inventive immunostimulatory composition may be a pharmaceutical composition or a vaccine.
Curevac Ag

Methods and compositions for inhibiting akt3

Compounds and compositions for selectively inhibiting akt3 are provided. Methods of using the compounds are also provided.
Augusta University Research Institute, Inc.

Adjuvanted influenza vaccines for pediatric use

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection.
Seqirus Uk Limited

Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response

Methods are disclosed for producing defective ribosomal products (drips) in blebs (dribbles) by contacting cells with a proteasome inhibitor, and in some examples also an autophagy inducer, thereby producing treated cells. Dribbles can be used to load antigen presenting cells (apcs), thereby allowing the apcs to present the drips and antigenic fragments thereof.
Providence Health & Services - Oregon

Computationally optimized broadly reactive antigens for influenza

The development of a computationally optimized influenza ha protein that elicits broadly reactive immune response to all h5n1 influenza virus isolates is described. The optimized ha protein was developed through a series of ha protein alignments, and subsequent generation of consensus sequences, for clade 2 h5n1 influenza virus isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Ompa and asp14 in vaccine compositions and as diagnostic targets

Anaplasma phagocytophilum surface proteins asp14 and ompa and homologous genes from anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Asp14 and/or ompa proteins or peptide fragments may be used in combination with other anaplasmatacaea surface proteins to elicit an immune response.
Virginia Commonwealth University

Transgenic algae for delivering antigens to an animal

Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter.
The Ohio State University

Novel immunotherapy against several tumors, such as lung cancer, including nsclc

The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases

The invention relates to an isolated interleukin-34 (il-34) polypeptide for use in preventing or treating graft rejection, autoimmune disease, unwanted immune response against therapeutic proteins and allergy. The invention also provides an in vitro method for determining whether a patient is at risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies, comprising a step of determining the expression level of il-34 in a biological sample obtained from said patient, wherein the presence of il-34 is indicative of a reduced risk of transplant rejection, autoimmune diseases, unwanted immune response against therapeutic proteins or allergies..
UniversitÉ De Nantes

Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Methods are provided for treating a subject with cancer, with a therapeutic dose of annexin v to the subject.. .
The Board Of Trustees Of The Leland Stanford Junior University

Pegylated recombinant bacteriophage

The present invention provides a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant. The present invention further provides methods of treatment of mammalian subjects having a bacterial infection by the administration of a pharmaceutically acceptable formulation of a recombinantly modified pegylated bacteriophage expressing a mammalian antigen presenting cell chemoattractant.

Specific akt3 inhibitor and uses thereof cross-reference to related applications

Methods of selectively inhibiting akt3 are provided. It has been discovered that 4-[(6-nitroquinolin-4-yl)amino]-n-[4-(pyridin-4-ylamino)phenyl]benzamide selectively inhibits akt3.
Augusta University Research Institute, Inc.

Psgl-1 modulators and uses thereof

The present invention relates to the seminal discovery that p-selectin glycoprotein ligand-1 (psgl-1) modulates the immune system and immune responses. Specifically, the present invention provides psgl-1 agonists and antagonists which increase the survival of multifunctional t cells and viral clearance.
Sanford-burnham Medical Research Institute

Antibody guided vaccines and methods of use for generation of rapid mature immune responses

Adjuvant compositions, vaccines, constructs for preparing the adjuvant compositions and vaccines and methods of using the adjuvant compositions and vaccines to enhance immune responses in subjects are provided herein. In particular, a rapid antibody response to the vaccine including both igg (in the circulation) and siga (mucosal secretory iga) is elicited.
The Texas A&m University System

Adjuvant for mucosal vaccine

An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response in a mucosal membrane. According to the present invention, an adjuvant for a mucosal vaccine containing a protein complex composed of hemagglutinin (ha) subcomponents ha1 and ha2, and mutant subcomponent ha3 of botulinum toxin is provided..
Osaka University

Vaccination in newborns and infants

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Microneedle compositions and methods of using same

Described herein, are microneedle devices comprising a recombinant alphavirus replicon encoding an exogenous polypeptide, wherein the recombinant alphavirus replicon is coated onto or embedded into a plurality of microneedles. Also described herein are methods of preparing a microneedle device comprising a recombinant alphavirus replicon encoding an exogenous polypeptide.
Verndari, Inc.

Novel method and compositions

The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants..
Glaxosmithkline Biologicals, S.a.

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Kif20a epitope peptides for th1 cells and vaccines containing the same

Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial..
Immune Design Corp.

A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

The invention concerns a method of preparing a composition comprising stimulated immune system cells such as dendritic cells (dc) for use in inducing immune response of cytotoxic t lymphocytes against colorectal cancer. The dendritic cells are pulsed by contact with colorectal cancer stem cells (csc) or their fragments thereof.
Tessa Therapeutics Pte. Ltd.

Anti-psgl-1 antibodies

Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to p-selectin glycoprotein ligand-1. Also disclosed are methods of inducing death of an activated t-cell and of modulating a t cell-mediated immune response in a subject..
Abgenomics Cooperatief U.a.

Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein

The present invention relates to an isolated immunogenic peptide comprising a v2 loop fragment from hiv surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from hiv-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-hiv-1 antibodies which protect against hiv-1 infection.
New York University

Immunomodulatory compositions and methods for treating disease with modified host defense peptides

Compositions and methods are provided for modulating an immune response in a vertebrate subject. Compositions and methods can comprise administering a modified host defense peptide to the vertebrate subject in an amount effective to activate the immune response in the vertebrate subject, wherein the modified host defense peptide is inverted in amino acid sequence from an amino terminus to a carboxy terminus or modified to one or more d-amino acids, or both modifications, when compared to a host defense peptide.
University Of Saskatchewan

Pharmaceutical combinations for immunotherapy

The present invention relates generally to a method for regulating immune reactions and test substances useful for same. Specifically, the method of the present invention relates to the modulation of the nerve growth factor receptor p75ntr, which is expressed by plasmacytoid dendritic cells.
Technische Universitat Dresden

Lipidated immune response modifier compound compositions, formulations, and methods

The compound n-(4-{[4-amino-2-butyl-1h-imidazo[4,5-c]quinolin-1-yl]oxy}butyl) octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.. .
3m Innovative Properties Company

Peptide mixture

There is disclosed a peptide mixture suitable for eliciting an immune response. It comprises a first and a second peptide, each corresponding to a fragment of the ras protein.
Targovax Asa

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

New medical agents and uses thereof

The invention provides a novel compounds derived from cd154, but without the intracellular domain. Notably, the invention provides tmz-cd154 and a method to treat diseases in which the novel molecule tmz-cd154 is used.
Lokon Pharma Ab

Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response

Disclosed herein are compositions and articles for wound healing that contain proteovesicles, comprising a syndecan polypeptide embedded in a lipid vesicle, and a pdgf polypeptide. Also disclosed is the use of these compositions to enhance wound healing..
Board Of Regents, The University Of Texas System

Immune mediated cancer cell destruction, systems and methods

Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.. .
Lazure Scientific, Inc.

Methods and materials for treating medical conditions

This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-interleukin 4, anti-interleukin 5, and/or anti-interleukin 13 antibodies to treat asthma in a mammal identified as having a th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided..
Mayo Foundation For Medical Education And Research

Methods for enhancing the efficacy of a tumor-directed immune response

As described below, the present invention features methods for enhancing the efficacy of a tumor antigen in inducing an anti-cancer immune response in a subject by administering an ox40 agonist and an indoleamine 2,3-dioxygenase (ido) inhibitor with the tumor antigen.. .
Augusta University Research Institute, Inc.

Synthetic glucopyranosyl lipid adjuvants

Or a pharmaceutically acceptable salt thereof, wherein l1, l2, l3, l4, l5, l6, l7, l8, l9, l10, y1, y2, y3, y4, r1, r2, r3, r4, r5, r6, are as defined herein. Pharmaceutical compositions, vaccine compositions, and related methods for inducing or enhancing immune responses, are also provided..

Vaccines with interleukin-17 as an adjuvant

Disclosed herein is a vaccine comprising an antigen and il-17. Also disclosed herein is a method for increasing an immune response in a subject.
Beijing Advaccine Biotechnology Co. Ltd

Vaccination with mrna-coded antigens

The present invention relates to vaccines comprising at least one mrna encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit..
Curevac Ag

Composite antigenic sequences and vaccines

The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection..
Longhorn Vaccines And Diagnostics, Llc

Cd40 ligand fusion protein vaccine

Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and cd40 ligand and also administering the encoded fusion protein.
Microvax, Llc

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Induced activation in dendritic cells

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide..
Baylor College Of Medicine

Breast and ovarian cancer vaccines

The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids.
University Of Washington Through Its Center For Commercialization

Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection

Vaccine, vectors and methods of using the vaccine vectors to enhance the immune response to an apicomplexan parasite and reduce the morbidity or mortality associated with subsequent infection are provided herein. The vaccine vectors include a polynucleotide encoding a rhomboid polypeptide and optionally include an immune-stimulatory polypeptide suitably expressed on the surface of the vaccine vector..
The Texas A&m University System

Rna-based compositions and adjuvants for prophylactic and therapeutic treatment

The present invention is directed towards an artificial rna nanostructure comprising multiple external strands of rna, each external strand comprising about 40-50 nucleotides; one internal strand of rna comprising more than about 50 nucleotides; the internal strands and external strands assembled to form a triangle nanostructure, a square nanostructure, or a polygon nanostructure and a prna three-way junction (3wj) motif at each vertex of the nanostructure. Such nanostructure can be provided in a composition together with an adjuvant for use in inducing the production of high affinity neutralizing antibodies or inhibitory antibodies, inducing the production of cytokines, inducing an immune response in a subject, or a combination thereof..
University Of Kentucky Research Foundation

Self assembling nucleic acid nanostructures

Stable self-assembling nucleic acid nanostructures comprising: —a plurality of oligonucleotides, —a plurality of g-quadruplex forming nucleic acids linked to the plurality of oligonucleotides, and —a plurality of g-quadruplex stabilizing domains linked to the g-quadruplex forming nucleic acids. The nucleic acid nanostructures are suitable for use as agonists or antagonists of nucleic acid interacting complexes, such as toll-like receptors; for inhibiting dna or rna expression; for stimulating or inhibiting an immune response; and for treating diseases such as cancer, infectious diseases, allergies and allergic diseases, and autoimmune diseases..
Exicure, Inc.

Compositions and methods relating to the treatment of diseases

The present invention relates to compositions and methods for promoting the induction of a cell-mediated immune response (such as that mediated by th1 cells) and the suppression of a humoral or allergic immune response (such as that mediated by th2 and th17 cells). In particular, the invention relates to compositions and methods for preventing or treating allergy, such as food allergy, and associated allergic diseases, and conditions where an exaggerated th17 response plays a detrimental role.
Alfacyte Ltd

Pharmaceutical compositions and methods to vaccinate against candidiasis

A candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of c.
Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

Treatment of infection

The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.. .

Vaccine

The present invention is based on the finding that microorganisms can be modified so as to express certain factors important in generating or raising host immune responses. In particular, the invention provides modified microorganisms which, when subjected to conditions which would be expected to suppress or reduce the expression, function and/or activity of certain factors, exhibit increased (often significantly increased) expression, and/or activity of those factors.
Moredun Research Institute

Immune health for companion animals

The invention provides methods for promoting and/or improving immune health in a companion animal. In one embodiment, a method for improving immune health in a companion animal, comprising administering a composition comprising non-replicating lactobacillus paracasei to the companion animal, wherein the composition is administered in an amount effective for increasing immune response in the animal..
Nestec Sa

Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Identification of pneumocystis antigens and uses thereof

Pneumonia due to the fungus pneumocystis jirovecii is a life-threatening infection that occurs in immunocompromised patients. The inability to culture the organism as well as the lack of a sequenced genome has hindered antigen discovery that could be useful in developing effective vaccines, therapeutic antibodies and diagnostic methods.
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

Immunotherapeutic composition, treatment, and diagnosis

Disclosed herein is a immunotherapeutic composition comprising il-17. Also disclosed herein is a method of increasing an immune response in a subject in need thereof.

Method and system for treating cancer cachexia

Various embodiments of the present invention are directed to the field of oncology, and in particular embodiments directed to a method of ameliorating, treating, or preventing a malignancy in a human subject wherein the steps of the method assist or boost the immune system in eradicating cancerous cells. In certain embodiments, administration of beneficial bacteria to an individual's microbiome that have been modified so as to produce effective amounts of desired compositions, compounds, agents, e.g.

Immune-modifying nanoparticles for the treatment of inflammatory diseases

The current invention involves the administration of negatively charged particles, such as polystyrene, plga, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles..
Cour Pharmaceuticals Development Company, Inc.

Early cancer detection and enhanced immunotherapy

A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time or original therapy and/or for later therapy.

Methods for treating cancer

A method for treating cancer comprising the steps of genetically sequencing a patient healthy tissue, genetically sequencing a patient tumor tissue, comparing the genetic sequences of the healthy tissue and tumor tissue to identify one or more mutations specific to the tumor tissue, generating a library of 9-mers having one or more peptide fragments specific to the tumor tissue, and identifying a 9-mer that elicits the strongest immune response in the patient.. .

Recombinant aav vectors useful for reducing immunity against transgene products

The disclosure in some aspects, relates to nucleic acids, compositions and kits useful for gene therapy with reduced immune response to transgene products.. .
University Of Massachusetts

Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

The invention relates to the regulated expression of a chimeric antigen receptor (car) within a lentiviral vector. The car comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the car to the cell membrane.
Institut National De La Sante Et De La Research Medical (inserm)

Immunostimulatory combinations of tlr ligands and methods of use

The present invention provides immunostimulatory combinations of tlr ligands and therapeutic and/or prophylactic methods that include administering an immunostimulatory combination to a subject. In general, the immunostimulatory combinations described herein can provide an increased immune response compared to other immunostimulatory combinations and/or compositions..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic

Immunotherapy composition and use thereof

The present invention relates to the field of preventing or reducing incidence or severity of an allergic immune response, and compositions for preventing or reducing incidence or severity of an allergic immune response. For example, the present invention provides compositions comprising inactivated and/or killed cells of helicobacter pylori or a cell lysate thereof, and methods and/or uses thereof for delaying or preventing or interrupting or slowing onset of one or more allergic conditions in a subject..
Ondek Pty Ltd

Novel vaccines against multiple subtypes of influenza virus

An aspect of the present invention is directed towards dna plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a dna plasmid and a pharmaceutically acceptable excipient. The dna plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (ha), neuraminidase (na), matrix protein, nucleoprotein, m2 ectodomain-nucleo-protein (m2e-np), or a combination thereof.
The Trustees Of The University Of Pennsylvania

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus filovirus immunogen including a consensus marburgvirus filovirus glycoprotein marv gp immunogen, a consensus ebolavirus sudan filovirus glycoprotein sebov gp immunogen and a consensus ebolavirus zaire glycoprotein zebov gp immunogen are disclosed. The coding sequences optionally include operable linked coding sequence that encode a signal peptide.
The Trustees Of The University Of Pennsylvania

Aipa, ompa, and asp14 in vaccine compositions and diagnostic targets for anaplasma phagocytophilum infection

Anaplasma phagocytophilum surface protein aipa and/or fragments thereof which comprise an invasin domain are used in compositions suitable to elicit an immune response to treat or prevent infections caused by tick-born bacteria of the anaplasmatacaea family. Aipa proteins and protein fragments or antibodies directed to aipa proteins and protein fragments are also used in diagnostic assays to detect exposure to and/or infection with anaplasmatacaea.
Virginia Commonwealth University

Replication defective adenovirus vector in vaccination

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Methods and compositions for transgene expression in a herpesvirus vector system

Compositions are provided comprising a replication-competent herpesvirus vector system and/or a herpesvirus vector particle comprising a heterologous recombinant transgene of interest encoding an antigen of interest (e.g., a tumor-associated antigen, a microbial antigen, etc.), wherein the recombinant transgene has been modified to comprise a codon usage signature of a herpesvirus late gene operably linked to an active promoter. Such compositions find use in a variety of methods including, for example, methods of generating an immune response against an antigen of interest in a subject in need thereof, as well as methods for treating or preventing cancer or a microbial infection..
President And Fellows Of Harvard College

Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Compositions and methods for modulation of rorgammat functions

The present invention relates to expression of rorγt in cells and tissues and the effect of expression of this gene on proliferation of specific immune cells and in promotion of immune cell aggregates and in induction of il17 producing cells. Furthermore, the invention relates to methods and agents that may decrease function of the gene product (the protein) or expression of this gene in individuals experiencing an inflammatory condition, an autoimmune disease or a food allergy, or any other condition whereby it is desirable to inhibit an immune response.

Anti-laminin4 antibodies specific for lg1-3

The invention provides antibodies that specifically bind to the lg1-3 modules of the g domain of laminin α4. The antibodies have the capacity to inhibit binding of laminin α4 to mcam.
Prothena Biosciences Limited

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Sulfated-glycolipids as adjuvants for vaccines

A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula i wherein n is 0 or 1; r is hydrogen or hydroxyl; and y is hydrogen or a sulfate group, at least one y being a sulfate group; and including pharmaceutically acceptable salts thereof.
National Research Council Of Canada

Laser adjuvants for enhancing immune response

Methods for enhancing an immune response to a vaccine using co-administration of radiation.. .
The General Hospital Corporation

Methods and compositions for liposomal formulation of antigens and uses thereof

The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“dmpc”); either dimyristoylphosphatidylglycerol (“dmpg”) or dimyristoyltrimethylammonium propane (“dmtap”) or both dmpc and dmtap; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s)..
The Regents Of The University Of California

Manf as a regulator of immune system function

Methods and compositions for enhancing an immunological response by administering an immunogenic composition comprising an effective amount of a manf family protein or fragment thereof and an antigen to a subject. Also, methods and compositions for decreasing an immune response by inhibiting or antagonizing the activity of a manf family protein..
University Of Massachusetts

Compositions and methods of enhancing immunogenicity of polysaccharide protein conjugates

The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided.
Kanvax Biopharmaceuticals Ltd

Method for the production of recombinant virus, dna constructs, recombinant virus and vaccine compositions

The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way they when cloned and expressed in the vector virus, the present in the 5′ region nucleotides present in the 5′ edge of the gene ns1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the steam and anchor of the protein e of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein e level and of constructural ns1 vector virus; (c) obtention of the non pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigene in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the flavivirus and/or other patogens..

Therapeutic cancer vaccine

The present invention relates to vaccine(s) comprising cancer cells expressing antigen(s), excipients, optionally adjuvant wherein the said antigen(s) is expressed on contacting the said cancer cell with p38 inducer, for use in treatment of cancer. The vaccine composition induces specific immune response against homologous and heterologus cancer cells of the tissue/organ.
Cadila Pharmaceuticals Ltd.

Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates

Methods and compositions for preventing an immune response to an immunogenic therapeutic agent [i.e. Anti-drug antibody (ada), a.k.a.
Jomoco, Corp.

Smart car devices and de car polypeptides for treating disease and methods for enhancing immune responses

In an aspect, the present invention relates generally to the field of treating disease with car devices, smart car devices, de car devices, and/or smart-de car devices. The present invention also relates generally to the genetic modification of cytotoxic t-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times.
Chimera Bioengineering, Inc.

Drug regulated transgene expression

The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring cd8+ central memory t cells or combinations of central memory t cells with cd4+ t cells that are genetically modified to express a chimeric receptor under the control of an inducible promoter. In some alternatives the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a chimeric antigen receptor comprising a ligand binding domain, a polynucleotide comprising a spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain under the control of a drug inducible promoter.
Seattle Children's Hospital (dba Seattle Children's Research Institute)

Induction of immunotolerance

The present invention provides for a novel method for inhibiting an undesirable immune response, especially in transplant recipients such as those having received an allogeneic stem cell transplant. Also disclosed are related compositions and kits for inducing immunotolerance..
The Chinese University Of Hong Kong

Recombinant swine influenza virus and uses thereof

Recombinant, chimeric porcine influenza viruses are disclosed that include hemagglutinin segments from more than one influenza virus subtype. Also described are methods of producing the recombinant influenza viruses, immunogenic compositions comprising the recombinant influenza viruses, methods of stimulating an immune response against influenza virus, and methods of treating and preventing influenza virus infection..
University Of Saskatchewan

Vaccines for human papilloma virus and methods for using the same

Improved anti-hpv immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus hpv39 e6e7 and hpv45 e6e7.
Inovio Pharmaceuticals, Inc.

Anti-mycoplasma spp. subunit vaccine

Provided in the present invention are anti-mycoplasma spp. Subunit vaccines, especially proteins suitable for being used as the active ingredient of the mycoplasma spp.
Agricultural Technology Research Institute

Enhanced immune response in cattle upon treatment with nitric oxide

The present invention relates to a method of immune activation which is effective for eliciting a non-antigen-specific immune response in a member of the bovine species. The method is particularly effective for protecting a member of the bovine species from infectious disease and treating animals inflicted with infectious disease..
Bovicor Pharmatech Inc.

Use of leukotriene b4 in combination with a toll-like receptor ligand, a rig-i-like receptor ligand, or a nod-like receptor ligand to enhance the innate immune response

The present invention relates to the use of leukotriene b4 to enhance the response of toll-like receptor (tlr), rig-i-like receptor (rlr), and nod-like receptor (nlr) when stimulated simultaneously with respective proper ligands. The use in combination of ltb4 with those ligands is useful to potentiate immune response for the treatment of autoimmune diseases, immunosuppressive diseases, as well as immunological disorders..
Universite De Laval

Compositions, kits and methods for in vitro antigen presentation, assessing vaccine efficacy, and assessing immunotoxicity of biologics and drugs

Nanoparticle-based compositions, assays, kits, methods and platforms for delivering an antigen (peptides, proteins) or a nucleic acid encoding an antigen to professional apcs (papcs) result in the generation of autologous apcs that present a natural peptide repertoire of the antigen for use in assessing the efficacy of a vaccine (e.g., a cytotoxic t lymphocyte (ctl) response to a particular antigen) or other therapy or intervention (cell-based therapy, adjuvant therapy, etc.). The compositions, kits, assays and methods also can be used for delivering a drug or biologic or portion thereof to apcs for assessing the immunogenicity of drugs and biologics.

Methods for the treatment of infections and tumors

Pd-1 antagonists are disclosed that can be used to reduce the expression or activity of pd-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these pd-1 antagonists in conjunction with an antigen from the infectious agent or tumor.

Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist.

Hbv polymerase mutants

The present invention relates to polymerase hbv mutant polypeptides comprising a mutated polymerase domain which is functionally disrupted for polymerase activity and fusion proteins comprising such polymerase mutant polypeptide. The present invention also relates to a nucleic acid molecule and an expression vector for expressing said polymerase mutant polypeptide as well as a composition which can be used for eliciting an immune response to hbv with the goal of providing a protective or therapeutic effect against hbv infection..

Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of alzheimer's disease and related tauopathies.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Novel peptides and combination of peptides for use in immunotherapy against various tumors

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.

Immobilized tumor necrosis factor-alpha muteins for enhancing immune response in mammals

An extracorporeal system for enhancing an immune response in a mammal to facilitate the elimination of a chronic pathology. The system includes an absorbent matrix capable of removing an immune system inhibitors such as soluble tnf receptor from the circulation of the mammal, thus, enabling a more vigorous immune response to the pathogenic agent.

Novel mucosal adjuvants and delivery systems

Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided.

Immunogenic combinations

Immunogenic combinations that include a) an immunogenic component containing a peptide or polypeptide antigen of a respiratory pathogen; and b) an immunogenic component containing a nucleic acid encoding an antigen of the same respiratory pathogen, wherein the immunogenic components are formulated for concurrent administration are provided, as well as methods for making and for administering such immunogenic combinations to elicit an immune response specific for the respiratory pathogen.. .

Dengue virus vaccine

Recombinant fusion proteins including a dengue virus eiii and an e2 subunit derived from a thermophilic bacterium are described. Also described are expression vectors including a polynucleotide that encodes the recombinant fusion protein and a promoter.

Immunotherapy using cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes

The present invention provides cell-targeting molecules which can deliver a cd8+ t-cell epitope cargo to the mhc class i presentation pathway of the cell. The cell-targeting molecules of the invention can be used to deliver virtually any cd8+ t-cell epitope from an extracellular space to the mhc class i pathway of a target cell, which may be a malignant cell and/or non-immune cell.

Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof

Disclosed herein are an immunogenic glycopeptide for inducing immune response to treat cancer. Other aspects of the present disclosure are pharmaceutical composition comprising the immunogenic glycopeptide; and method for preventing and/or treating a cancer..

Cmv vectors comprising microrna recognition elements

Disclosed herein are recombinant cmv vectors comprising heterologous antigens and microrna recognition elements to silence expression of cmv genes in the presence of microrna derived from myeloid cells, an active ul128 protein and an active ul130 protein. Also disclosed are recombinant cmv vectors comprising heterologous antigens and microrna recognition elements to silence expression of cmv genes in the presence of microrna derived from myeloid cells, an inactive ul128 protein and an inactive ul130 protein.

Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders

The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.. .

Adenosine receptor agonists and antagonists to modulate t cell responses

Described are uses of a2a adenosine receptor antagonists and agonists to provide long term modulation of immune responses. A2a receptor antagonists in particular are provided to enhance immune responses by reducing t-cell mediated tolerance to antigenic stimuli and agonists are provided to enhance effectiveness of immunosuppressive agents.

Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom

The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an ox40l polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the ox40l polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone.
Merial, Inc.

Therapeutic antibodies

A pharmaceutical comprising a therapeutic protein that binds to a therapeutic target, the protein being modified with a compound that inhibits binding of the protein to the therapeutic target, the modified protein being effective for reducing an immune response against the protein and for producing a therapeutic effect by binding to the therapeutic target. The therapeutic protein may be an antibody that includes an antibody combining site that binds to the therapeutic target..

Gitr antibodies and methods of inducing or enhancing an immune response

The present invention provides binding molecules that specifically bind to gitr, e.g., human gitr (hgitr), on t cells and dendritic cells. Binding molecules of the invention are characterized by binding to hgitr with high affinity, in the presence of a stimulating agent, e.g., cd3, are agonistic, and abrogate the suppression of teff cells by treg cells.
Gitr, Inc.

Ctla4 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1/ctla4 binders

The present invention provides multispecific molecules, e.g., comprising more than one isvd or nanobody, that bind to pd1 and ctla4. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Pd1 and/or lag3 binders

The present invention provides molecules, such as isvds and nanobodies, that bind to pd1 and lag3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule.

Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof

The present invention provides isolated monoclonal antibodies that specifically bind lag-3, and have optimized functional properties compared to previously described anti-lag-3 antibodies, such as antibody 25f7 (us 2011/0150892 a1). These properties include reduced deamidation sites, while still retaining high affinity binding to human lag-3, and physical (i.e., thermal and chemical) stability.
Bristol-myers Squibb Company

Tgf-ß1 specific antibodies and methods and uses thereof

Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (tgf-β1) are provided, particularly recognizing human and mouse tgf-β1 and not recognizing or binding tgf-β2 or tgf-β3. Particular antibodies are provided which specifically recognize and neutralize tgf-β1.

Induction of immune response

Provided are methods and compositions that can he used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, dna constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue..
Drexel University

Pharmaceutical compositions comprising cpg oligonucleotides

The present invention provides a pharmaceutical composition for inducing immune response in a subject, comprising: (a) an antigen with a concentration ranging from 1 μg/ml to 100 μg/ml; (b) cpg oligonucleotides having a sequence of 5′-tcgacgttcgtcgttcgtcgttc-3′, with a concentration ranging from 25 μg/ml to 500 μg/ml, and (c) an aluminium adjuvant with a concentration ranging from 25 μg/ml to 500 μg/ml. Such pharmaceutical composition can induce or boost immune response against antigen in the subject..
Changchun Huapu Biotechnology Co., Ltd.

Vaccines comprising heat-sensitive transgenes

The present disclosure provides temperature sensitive essential nucleic acid molecules from a psychrophilic bacterium, proteins encoded by the nucleic acid molecules, as well as recombinant cells into which have been introduced such nucleic acid molecules. The disclosed recombinant cells containing one or more essential nucleic acid molecules from a psychrophilic bacterium are thereby made temperature sensitive, and can be administered to a mammal to induce an immune response in the mammal..
Uvic Industry Partnerships Inc.

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition, wherein a lower dose is given in the second administration than in the first administration, and wherein the second administration may be unadjuvanted.. .
Glaxosmithkline Biologicals Sa

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Method for reducing the immune response to a biologically active protein

A new use of a molecule comprising at least one moiety which is a biologically active protein and at least one moiety capable of binding to a serum albumin of a mammal is provided, for preparation of a medicament which elicits no or a reduced immune response upon administration to the mammal, as compared to the immune response elicited upon administration to the mammal of the biologically active protein per se. Also provided is a method of reducing or eliminating the immune response elicited upon administration of a biologically active protein to a human or non-human mammal, which comprises coupling the polypeptide to at least one moiety capable of binding to a serum albumin of the mammal..
Syngenta Participations Ag

Methods and compositions for diagnosing, monitoring and treating cancer

The invention relates to methods for diagnosing cancer and determining the responsiveness to chemotherapyin a subject based on the detection of hsp70-expressing exosomes in a bodily fluid sample obtained from said subject. The invention also relates to methods for treating cancer and in particular methods for restoring or enhancing the anti-tumor immune response in a patient in need thereof by inhibiting the activation mdsc as well as methods for inhibiting or reducing hsp70-expressing exosomes-mediated tumor resistance against a chemotherapeutic agent and therefore methods for restoring or enhancing the efficacy of said chemotherapeutic agent..
Universite De Bourgogne

Humanized viral vectors and methods of use thereof

The present invention provides humanized viral vectors and methods of use thereof for delivery of transgenes or therapeutic nucleic acids to human subjects. Humanized viral vectors are modified from known viral vectors such as those based on aav by coating their surface with a human protein such as human serum albumin and optionally a lipid coating or formulation, so that the foreign or non-human nature of the vector is masked.
The Children's Hospital Of Philadelphia

Calcium flux agonists and methods therefor

Calcium flux agonists are used to enhance a tlr- or nod-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include ca2+ ionophores and serca inhibitors and are used in synergistic quantities where a ligand to a tlr or nod receptor is present..
Nant Holdings Ip, Llc

Polyvalent influenza virus-like particles (vlps) and use as vaccines

This disclosure provides compositions that include a mixture of viral like particles (vlps), expressing different individual influenza hemagglutinin (ha) proteins that elicit broadly reactive immune responses to a wide variety of influenza viruses. For example, the composition can include at least two different influenza vlps, a first vlp comprising a first ha polypeptide and a second vlp comprising a second influenza ha polypeptide, wherein the first and the second ha polypeptide are different subtypes and/or are from different influenza viruses, and a pharmaceutically acceptable carrier and/or an adjuvant.
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Use of oil and water emulsions for increasing b cell responses with modified vaccinia ankara virus

The invention relates to compositions, uses, and methods for inducing an immune response against a vaccinia virus. The addition of an oil and water emulsion to mva can vastly increase the b cell response and particularly neutralizing antibodies against vaccinia virus and encoded recombinant antigens.
Bavarian Nordic A/s

Attenuated mannheimia haemolytica vaccines and methods of making and use

The present invention provides attenuated m. Haemolytica strains that elicit an immune response in animals against m.
The United States Of America As Represented By The Secretary Of Agriculture

Capsular gram-positive bacteria bioconjugate vaccines

The present invention encompasses a novel s. Aureus bioconjugate vaccine.
Glycovaxyn Ag

Anti-malaria compositions and methods

Described herein are multilayer films that include modified polypeptide epitopes from plasmodium falciparum, specifically a modified t* epitope. The multilayer films are capable of eliciting an immune response in a host upon administration to the host.
Artificial Cell Technologies, Inc.

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Recombinant viral vectors and methods for inducing a heterosubtypic immune response to influenza a viruses

The present invention relates to recombinant viral vectors and methods of using the recombinant viral vectors to induce an immune response to influenza a viruses. The invention provides recombinant viral vectors based, for example, on the non-replicating modified vaccinia virus ankara.
Nanotherapeutics, Inc.

Blockade of rgmb for reducing transplantation-associated immune responses

Rgmb antagonists reduce undesirable immune responses associated with tissue or organ transplantation.. .
The Board Of Trustees Of The Leland Stanford Junior University

Using b-cell-targeting antigen igg fusion as tolerogenic protein therapy for treating adverse immune responses

The present invention generally relates to antigen-specific tolerogenic protein therapy and the use thereof for treating adverse immune responses, including those associated with autoimmune diseases such as multiple sclerosis (ms) and hemophilia. In particular, the invention involves the application of a b cell-targeting igg fusion protein as the antigen-specific tolerogenic protein therapy, either alone or in combination with inhibitory antibodies.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.

Computationally optimized broadly reactive antigens for h1n1 influenza

Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2011.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response

The present invention relates to the use of a recombinant lag-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer..
Immutep

Dengue virus specific multiple hla binding t cell epitopes for the use of universal vaccine development

Dengue fever (df) and dengue hemorrhagic fever (dhf) are significant global public health problems and understanding the overall immune response to infection will contribute to appropriate management of the disease and its potentially severe complications. Live attenuated and subunit vaccine candidates, which are under clinical evaluation, induce primarily an antibody response to the virus and minimal cross-reactive t cell responses.
Immunotope, Inc.

Fusion molecule based on novel taa variant

This invention provides novel carbonic anhydrase (caix) nucleic acid and peptide sequences, as well as related methods and compositions, including anti-cancer immunogenic agent(s) (e.g. Vaccines and chimeric molecules) that elicit an immune response specifically directed against cancer cells expressing a caix antigenic marker.
The Regents Of The University Of California

Methods and compositions for modulating immune tolerance

The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing t cell mediated immune response useful in the treatment of cancer and chronic infection..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic

Vaccines for use in the prophylaxis and treatment of influenza virus disease

Provided herein are polypeptides comprising portions of the influenza virus hemagglutinin, compositions comprising such polypeptides that can be used as immunogens in vaccines and methods of their use to generate an immune response against multiple influenza subtypes in a subject.. .
Plant Genetics International Limited

Useful process for screening immune response modifier

Immunovir and components were isolated from pyrus serotina rehder and other species of rosaceae by column chromatography.. .

Expression of mirnas in placental tissue

Provided are human mirnas associated with the generation of immunological tolerance during pregnancy as well as fragments, derivatives and variants thereof for use in immunomodulation. Said mirnas may be used in diagnosis and treatment of disorders associated with a deregulated immune response, autoimmune disorders, pregnancy associated diseases, failure or problems of placentation and complications resulting from allotransplantations.

Chimeric west nile/dengue viruses and methods of use

Disclosed herein are chimeric flaviviruses including non-coding regions, non-structural proteins, and at least a portion of a c protein from west nile virus (wnv), and a prm protein and an e protein from dengue virus (denv). The denv may be den1 serotype, den2 serotype, den3 serotype, or den4 serotype.
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services

Computationally optimized broadly reactive antigens for h1n1 influenza

Described herein is the generation of optimized h1n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h1n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on selected h1n1 viruses isolated from 1918-2012.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Vesicular stomatitis virus for prime boost vaccine

The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51.
The University Of Western Ontario

Novel compound having immune disease treatment effect and use thereof

The present invention relates to a novel compound capable of effectively preventing and treating immune diseases and a use thereof. The novel compound of the present invention has effects of inhibiting the production of inflammatory cytokines, increasing the activity of regulatory t cells having immunoregulatory functions, inhibiting the production of auto-antibodies to regulate excessive immune responses, and inhibiting the differentiation of osteoclasts, and thus can be used for treating immune diseases, such as autoimmune disease, inflammatory disease, and transplant rejection diseases, which are caused by abnormal regulation of various kinds of immune response.
The Catholic University Of Korea Industry-academic Cooperation Foundation

Vista modulators for diagnosis and treatment of cancer

The present disclosure relates to compositions and therapeutic methods for activating an immune response in a patient in need thereof. In a preferred embodiment, the subject methods and compositions are able to antagonize the activity of vista, a naturally occurring “checkpoint” protein which contributes to immune tolerance, optionally in combination with an antagonist of a second checkpoint pathway such as pd-1.
The Trustees Of Dartmouth College

Vesicular stomatitis virus for prime boost vaccine

The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51.
The University Of Western Ontario

Novel methods for inducing an immune response

Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an m72 related antigen and wherein a subsequent administration is delayed.. .
Glaxosmithkline Biologicals S.a.

Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors

The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of uniprot #p05112 and/or the ligand of uniprot #p35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the th2 immune response.
Pieris Pharmaceuticals Gmbh

Methods of using anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity

The present application relates to anti-pd-l1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance t-cell function to upregulate cell-mediated immune responses and for the treatment of t cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.. .
Genentech, Inc.

Computationally optimized broadly reactive antigens for human and avian h5n1 influenza

Described herein is the generation of optimized h5n1 influenza ha polypeptides for eliciting a broadly reactive immune response to h5n1 influenza virus isolates. The optimized ha polypeptides were developed through a series of ha protein alignments, and subsequent generation of consensus sequences, based on human and avian h5n1 isolates.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education

Cytokine-chitosan bioconjugates and methods of using the same

Compositions including chitosan covalently linked to a cytokine or growth factor are provided herein. The compositions can be used to produce pharmaceutical compositions and can be used in methods of treating a variety of diseases or disorders.
The Board Of Trustees Of The University Of Arkansas

Cellular vaccine and inducing an immune response in a subject

The present invention relates to methods of inducing or enhancing an immune response against an immunogen in a subject. The invention further includes isolated nucleic acid vaccines, cellular vaccines, fusion proteins, expression vectors, vaccines, and immunogenic compositions for use therein..
Adelaide Research & Innovation Pty Ltd.

Influenza virus vectors and uses therefor

Disclosed herein are compositions and methods related to mutant viruses, and in particular, mutant influenza viruses. The mutant viruses disclosed herein include a mutant m2 sequence, and are useful in immunogenic compositions, e.g., as vaccines.
Flugen, Inc.

Haemophilus influenzae type iv pili

The invention described herein relates to a haemophilus influenzae (h. Influenzae) regulon encoding type iv pili.
Nationwide Children's Hospital, Inc.

Influenza vaccine, composition, and methods of use

The invention relates to compositions and vaccines that include a mutated bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine..
National University Of Singapore

Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system

Recombinant strains of mycobacterium bovis bacille calmette-guerin (m. Bovis bcg) comprising a heterologous nucleic acid sequence of mycobacterium marinum (m.
Institut Pasteur

Multi-component-multistage malaria vaccines

The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different plasmodium falciparum antigens from the pre-erythrocytic the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans.
Fraunhofer-gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Methods and compositions for treating autoimmune and inflammatory conditions

Described herein are compositions and methods for inhibiting an inflammatory or autoimmune response and for inducing immune tolerance in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an antigen presenting cell (apc)-targeted antibody operatively linked to il-10 or a fragment thereof. The compositions and methods described herein are useful for treating inflammatory and autoimmune disorders..
Baylor Research Institute

Flavonoid compositions and methods of use

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin.
Reoxcyn Discoveries Group, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Method for decreasing immunogenicity of protein and peptide

The present invention relates to a method for increasing serum half-life of a protein or peptide and decreasing immunogenicity thereof by site-specifically binding a carrier to a protein or peptide, and to the use thereof. The conjugate of the physiologically active protein or peptide of the present invention can significantly decrease immunogenicity in the human body and thus reduce antibody production rate against the protein or peptide.
Hanmi Pharm. Co., Ltd.

Activation of immune-related signaling pathways in cells via optofection

Systems and methods of inducing large-scale optical transfection and generation of an immune response in target cells are presented. In preferred aspects large-scale optofection uses nanoparticles with target specific affinity moieties to generate cavitation events proximal to the cell membrane of cells to which the nanoparticles are attached, and suspended and/or dissolved cargo is so provided access into the cell.
Nant Holdings Ip, Llc

Induction of mucosal tolerance to antigens

The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of foxp3+ and/or il-10 and/or tgf-β producing regulatory t-cells, capable of suppressing undesired immune responses toward an antigen, by oral delivery of said antigen in combination with an immunosuppressing cytokine secreting micro-organism..
Intrexon Actobiotics Nv

Combination vaccines with serogroup b meningococcus and d/t/p

Serogroup b meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids (“dtp”) to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type dtp ratios.
Glaxosmithkline Biologicals Sa

Amplification of epitope specific personalized anti-angiogenic immune responses

Disclosed are therapeutic means, protocols, and compositions of matter useful for treatment of cancer by eliciting and amplifying immune responses specific to antigens found on tumor endothelium. In one embodiment of the invention a patient is immunized with a polyvalent anti-angiogenic vaccine, subsequent to which assessment is made in a patient specific manner of the immune targets that are recognized in response to the immunizing mixture.
Batu Biologics, Inc.

Strategies to prevent and/or treat immune responses to soluble allofactors

The present invention relates to the use of immunogenic peptides comprising a t-cell epitope derived from a soluble allofactor and a redox motif such as c-(x)2-[cst] or [cst]-(x)2-c in the prevention and/or suppression of immune responses to said soluble allofactor and in the manufacture of medicaments therefore.. .
Life Sciences Research Partners Vzw

Methods and compositions for immunomodulation

The methods and uses described herein relate to the modulation of the immune system by modulation of sema3f levels and/or activity, e.g. Suppressing allograft rejection or inflammation by administering a sema3f agonist or increasing an immune response by administering a sema3f inhibitor..
Children's Medical Center Corporation

Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy

Disclosed are compositions of matter, therapeutic protocols, and immunization means to induce an active immune response to vasculature feeding glioma or other brain neoplasia. In one embodiment the invention provides administration of placental derived endothelial cells at concentrations of 10 million to 50 million administered in a manner to stimulate immunity toward blood vessels supplying glioma or other brain neoplastic malignancies.
Batu Biologics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Mature dendritic cell compositions and methods for culturing same

This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (dcs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (idcs) with a first signal comprising an interferon gamma receptor (ifn-γr) agonist and/or a tumor necrosis factor alpha receptor (tnf-αr) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a cd40 agonist to produce ccr7+ mature dendritic cells.
Argos Therapeutics, Inc.

Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cyaa-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses

The invention relates to a chimeric protein comprising or consisting of, from n-terminal to c-terminal, (a) a n-terminal part of a bordetella cyaa protein (b) a heterologous polypeptide, and (c) a c-terminal part of a bordetella cyaa protein. The invention also relates to a polynucleotide encoding a deleted version of a bordetella cyaa, as well as a polynucleotide encoding this chimeric protein.
Genticel

Inhibition of gliadin peptides

Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation

Amino acid and peptide conjugates and conjugation process

The present invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, pharmaceutical compositions comprising the conjugates, methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same.. .
Auckland Uniservices Limited

Inhibition of tumor angiogenesis by checkpoint inhibitors and active vaccination

Disclosed are compositions of matter, methods, and protocols useful for treatment of cancer through induction of anti-angiogenic immune responses by vaccination together with immune modulation triggered by checkpoint inhibitors. The invention provides placenta, placental endothelial, placental fibroblasts, and mixtures thereof as immunogens, whose anti-angiogenic activity is augmented by utilization of checkpoint inhibitors.
Batu Biologics, Inc.

Lectin compositions and methods for modulating an immune response to an antigen

The present invention provides a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide, as well as a vector comprising a nucleic acid encoding for such a fusion polypeptide, and a host cell comprising such nucleic acid. The present invention also provides a composition comprising an antigen bearing target and such a fusion polypeptide, as well as a composition comprising a virus or a cell and such a fusion polypeptide.
Opsanitx Llc

Methods and compositions for eliciting an immune response against hepatitis b virus

The present invention relates to immunization of hypo-responsive groups of individuals. In particular, the present invention provides methods and compositions for eliciting a potent immune response to hepatitis b virus in individuals in need thereof..
Dynavax Technologies Corporation

Hendra virus recombinant compositions and uses thereof

The present invention provides vectors that contain and express in vivo or in vitro one or more hendra virus polypeptides or antigens that elicit an immune response in animal or human against hendra virus and nipah virus, compositions comprising said vectors and/or hendra virus polypeptides, methods of vaccination against hendra virus and nipah virus, and kits for use with such methods and compositions.. .
Merial, Inc.

Medicament for use in a inducing or extending a cellular cytotoxic immune response

The present invention relates to a medicament for use in a method of extending a cellular cytotoxic immune response against an antigen-comprising protein, the method comprising the step of: i) administering to a patient having t cells activated against an antigen a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and an adjuvant which supports a th-1-mediated response, wherein the peptide is derived from the antigen-comprising protein, thereby re-activating the activated t cell, wherein the peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell of step i) is administered in a time frame of from 0 h to 14 days after the t cells were activated against an antigen.. .
Bundesrepublik Deutschland Ietzvertreten Durch Das Robert Koch-institut Vertreten Durch Seinen Präsi

Genetic engineering of macrophages for immunotherapy

Disclosed are methods of making a genetically modified immune cell for modifying a tumor microenvironment (tme) and methods of modifying a tumor microenvironment (tme). In some embodiments, the method can include delivering a first vector to an immune cell, wherein the first vector comprises a nucleic acid encoding a protein that induces t-cell proliferation, promotes persistence and activation of endogenous or adoptively transferred nk or t cells and/or induces production of an interleukin, an interferon, a pd-1 checkpoint binding protein, hmgb1, myd88, a cytokine or a chemokine.
Seattle Children's Hospital (dba Seattle Children' S Research Institute)

Malaria antigen screening method

The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (apcs) in vitro or to an animal in vivo.
University Of Georgia Research Foundation, Inc.

Recombinant poxvirus vector comprising tetanus toxin fragment c

The present invention relates to a recombinant poxvirus comprising tetanus toxin fragment c for improved immunogenicity of an antigen and related methods and uses. Specifically, the present invention generally relates to genetically engineered (recombinant) poxvirus vectors comprising a tetanus toxin fragment c (ttc) coding sequence operably linked to a bacterial antigenic determinant as well as to uses thereof, e.g., to affect an immune response in a subject..
Bavarian Nordic A/s

Immunomodulating beta-1,6-d-glucans

This invention relates to modifications of β-1,6-d-glucans, e.g., structures according to formula (i), and the ability of these compositions to modulate an immune response.. .
Immunexcite, Inc.

Regulatable chimeric antigen receptor

Provided are compositions and methods relating to regulatable chimeric antigen receptors (rcars), natural killer cell receptor cars (nkr-cars), and regulatable nkr-cars (rnkr-cars), where the intracellular signaling or proliferation of the rcar or rnkr-car can be controlled to optimize the use of an rcar/nkr-car- or rnkr-car-expressing cell to provide an immune response. Cells can be engineered to express a rnkr-car or to express a rcar and a nkr-car (e.g., inhibitory nkr-car).
The Trustees Of The University Of Pennsylvania

Mesothelin-targeted chimeric antigen receptors and uses thereof

The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (cars) that specifically target human mesothelin, and immunoresponsive cells comprising such cars.
The U.s.a. As Represented By The Secretary, Department Of Health And Human Services

Peptide antagonist of ll-37

This disclosure is related to the peptide antagonist of ll-37, an antimicrobial peptide that has multiple functions in both innate and adaptive immune response. Specifically, the identified peptide antagonists of ll-37 provide inhibition to detrimental autoimmune inflammatory response, whereas at the same time retain ll-37's antibacterial activity..
Janssen Biotech, Inc.

Composition and diagnosis and immunotherapy of lung cancer

The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic t lymphocyte specific immune response to at least one of sp17, akap-4, or pttg1 expressed by one or more lung cancer cells.. .
Texas Tech University System

Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Modified adenoviruses for cancer vaccines development

The present invention relates to adenoviral vectors, wherein the viral capsid has been coated with polypeptides, which are capable of stimulating a peptide-specific immune response in a subject and uses thereof. Furthermore, the present invention relates to methods of treating diseases, e.g.
Helsingin Yliopisto

A medicament for use in a inducing or extending a cellular cytotoxic immune response

The present invention relates to a medicament for use in a method of inducing a cellular cytotoxic immune response, the method comprising the steps of: i) administering to a patient a delivery system comprising (a) a molecule binding to a receptor on the surface of a dendritic cell, (b) an antigen-comprising protein bound to molecule of (a) and (c) a first adjuvant, wherein upon binding of the molecule of (a) to the receptor, the protein of (b) is internalized and processed in the dendritic cell and the antigen comprised in the protein is presented on the surface of the dendritic cell, thereby activating a t cell in the patient; and ii) administering to the patient a re-activator selected from the group consisting of (d) complexed interleukin 2 (il-2cx), (e) a peptide-loaded major histocompatibility complex class i (mhc-i) presenting cell and a second adjuvant, and (f) a combination of (d) and (e), wherein the peptide is derived from the antigen-comprising protein as defined in step i), thereby reactivating the t cell activated in step i), wherein the re-activator of step ii) is administered in a time frame of from 0 h to 14 days after the administration of the delivery system of step i).. .
Bundesrepublik Deutschland Ietztvertreten Durch Da S Robert Koch-institut Vertreten Durch Seinen Prä

Methods and compositions for increasing a t-effector cell to regulatory t cell ratio

The present invention is directed to methods for increasing t-cell effector cell to regulatory t cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant listeria strain, comprising a fusion peptide that comprises an llo fragment and tumor-associated antigen..
National Institutes Of Health (nih), U.s. Dept. Of Health And Humans Services (dhhs), U.s. Governmen

Flavonoid compositions and methods of use

Flavonoid compositions containing the flavonoid quercetin and/or derivatives of quercetin are disclosed. The flavonoid compositions are formulated to improve the bioavailability of quercetin.
Reoxcyn Discoveries Group, Inc.

Humanized monoclonal antibodies and methodsof use

The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.

Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function

Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital

Compositions and methods for anti-lyst immunomodulation

Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage.
Research Institute At Nationwide Children's Hospital

Particulate vaccine formulations for inducing innate and adaptive immunity

Disclosed are compositions, kits, and methods for inducing an immune response against an infection or a disease. The compositions typically include biodegradable particles having an average effective diameter that such that the biodegradable particles are phagocytosed by antigen presenting cells when the biodegradable particles are administered to a subject in need thereof.
Auburn University

A composition comprising ex-vivo generated dendritic cells

The present invention relates to a composition comprising ex-vivo generated antigen-loaded dendritic cells in combination with β-glucan and hyaluronic acid or pharmaceutically acceptable derivatives thereof and methods of preparing and delivering the same. The present composition of the present invention enhances antigen-specific t cell response against cancer cells.

Novel immunogenic composition

Recombinant chimeric viruses based on ndv lasota strain and containing either iltv gb or gd are produced. Administration of the chimeric viruses to chickens induces an immune response in the animal against both ndv and iltv.
The United States Of America, As Represented By The Secretary Of Agriculture

Multivalent vlp conjugates

The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc

Antigen specific multi epitope vaccines

The presently described subject matter relates to cancer vaccines composed of the signal peptide domain of tumor associated antigens or proteins. The described peptide vaccines have multiple mhc class i and class ii epitopes which are highly abundant in the population.
Vaxil Biotherapeutics Ltd.

Tumor vaccination involving a humoral immune response against self-proteins

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis b virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject..
Biontech Ag

Prenatal therapy to induce immune tolerance

Constructs and methods for inducing immune tolerance during gestation, e.g. In utero, are provided.
Inserm (institut National De La Santé Et De La Recherche Médicale)

Enhancing serological assays via fusion proteins

A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
Cornell University

Attenuated viruses useful for vaccines

This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject.
The Research Foundation For The State University Of New York

Method for in situ inhibition of regulatory t cells

The present invention pertains to engineered t-cells, method for their preparation and their use as medicament, particularly for immunotherapy. The engineered t-cells of the invention are designed to express both a chimeric antigen receptor (car) directed against at least one antigen expressed at the surface of a malignant or infected cell, and a secreted inhibitor of regulatory t-cells (treg).
Cellectis

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(om)o;(xaa)x with the majority of residues being selected from arg, lys, his, om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Chimeric vaccines

The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein.
The Johns Hopkins University

Vesicular stomatitis virus for prime boost vaccine

The present invention relates to vesicular stomatitis virus (vsv) matrix (m) protein mutants. One mutant m protein includes a glycine changed to a glutamic acid at position 21, a leucine changed to a phenylalanine at position 111 and a methionine changed to an arginine at position 51.
The University Of Western Ontario

Methods and compositions for producing an adenovirus vector for use with multiple vaccinations

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Adenoviral vector vaccine

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of cd40 ligand, which is missing all or substantially all of the transmembrane domain rendering cd40l secretable.
Vaxum, Llc

Method and composition for modulating immune response

Provided is a method for modulating an immune response which is not derived from alphavirus infection comprising administering to a subject in need thereof an effective amount of a composition comprising an alphavirus virus like particle.. .
Vlp Therapeutics, Llc

Methods of modulating an immune response

The present invention relates to methods of modulating an immune response in a subject by using a binding protein (e.g., an antibody or an antigen-binding portion of an antibody) to mask or alter an epitope on an antigen that is administered to the subject. Such methods are useful for inducing an immune response (e.g., production of an antibody) in the subject to a non-immunodominant epitope on the antigen.
Cangene Corporation

Process for preparing an attenuated tetravalent dengue vaccine

The present invention refers to a process for preparing an attenuated tetravalent dengue vaccine and its product. The present invention also refers to a process for preparing a tetravalent dengue vaccine for administration to a subject, to a method for inducing an immune response to virus dengue serotype 1, 2, 3 and 4 in a patient and to a tetravalent dengue vaccine kit..
Fundacao Butantan

Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis

The present invention generally provides methods and compositions for eliciting an immune response against neisseria spp. Bacteria in a subject, particularly against a neisseria meningitidis serogroup b strain..
Children's Hospital & Research Center Oakland

Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent

There is disclosed at least one peptide suitable for eliciting an immune response, for use in the treatment of cancer. The, or each, peptide corresponds to a fragment of the ras protein, but has one to three point mutations thereof.
Targovax Asa

Sequential administration of a replication defective adenovirus vector in vaccination protocols

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.. .
Etubics Corporation

Rna viruses for immunovirotherapy

The present invention relates to a recombinant virus of the family paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer..
Ruprecht-karls-universitat Heidelberg

Compositions and methods for intradermal vaccine delivery

The present invention relates, generally, to compositions comprising at least one antigen encapsulated within at least one fibrous polymer matrix and their use in intradermal vaccine delivery. It has been discovered that the intradermal delivery of antigens into the antigenpresenting cell-rich layers of the skin requires less antigen than traditional vaccine delivery methods and is still capable of eliciting an immune response comparable to that observed with traditional vaccine delivery methods..
The Research Foundation For The State University Of New York

Method of activating immune response in plants

A method of enhancing plant immunity is provided. The method comprises the step of administering to a plant a small molecule that binds to npr1, or a functionally equivalent homolog thereof, that disrupts the interaction between n-terminal btb/poz domain and the c-terminal transactivation domain of npr1.

Plant pattern recognition receptor and chimeras thereof for use against bacterial infections

The present invention relates to the finding that an until now orphan protein named receptor-like protein 1 (rlp1) in plants mediates an immune response to bacterial infections. Specifically, the invention relates to rlp1, now named receptor of enigmatic microbe-associated molecular pattern (mamp) of xanthomonas (remax), in arabidopsis thaliana remax was found to recognise the presence of xanthomonas and to initiate an immune signalling that eventually yields into a typical plant immune responses to bacterial infections.
Eberhard Karls Universitaet Tuebingen

Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways

Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.

Virus like vesicles (vlvs) based vaccines to prevent or treat chronic hepatitis b virus (hbv) infection

The present invention relates to the discovery of compositions and methods for therapeutic immunization for treatment of chronic hepatitis b. Methods of the invention include a method generating an evolved high titer hybrid-hepatitis b virus (hbv) vector, methods of treating and/or preventing hbv, and methods of inducing a memory t and b cell immune response against hbv infection in a subject administered the vlv composition produced thereby.
Yale University

Adenoviral vector-based vaccine against enterovirus infection

The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a pi protein and a 3 cd protease of an enterovirus.
Lu-hai Wang

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Histone deacetylase 6 inhibition for enhancing t-cell function during anti-tumor response and tumor-peptide vaccination

Disclosed are methods whereby an effective amount of a hdac6 inhibitor is used to activate a subjects t-cell response to tumor or tumor vaccine. Methods of using hdac6 inhibitors to increase a subjects anti-tumor immune response, alone or in conjunction with other tumor treatments, are also disclosed..
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Io Biotech Aps

. .

Biomarkers for prostate cancer and methods for their detection

The invention provides a method for predicting the clinical response to a cancer vaccine in a patient having cancer, a method for determining the immune response to a cancer vaccine in a patient having cancer who has been administered a cancer vaccine, a method for determining the long-term survival in a patient having cancer, corresponding kits therefor, as well as methods of for improving the efficacy of a virus-based vaccine.. .
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Evolution of high-titer virus-like vesicles for vaccine applications

The present invention relates to the discovery of a high titer hybrid-virus vector that gives rise to high titer virus like vesicles (vlvs) that can be used as a vaccine. The invention includes compositions and methods of generating an evolved hybrid-virus vector vaccine and selecting high titer vlvs, methods of treating and/or preventing or immunizing against, a specific disease or disorder, and methods of inducing a memory t cell and b cell immune response in a subject administered the vlv composition produced thereby.
Yale University

Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

The present invention provides antibodies that bind to prostate-specific membrane antigen (psma), bispecific antibodies that bind to psma and cd3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human psma with high affinity and bind cd3 to induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.

Method of providing monoclonal auto-antibodies with desired specificity

Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
Immunoqure Ag

Factor viii b cell epitope variants having reduced immunogenicity

Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
Bloodworks

Plasmodium falciparum antigens

The invention relates to antigens, associated with sterile immunity, and methods of their use, in an immunogenic formulation to confer an immune response against plasmodium falciparum. The inventive antigens were identified by their association with sterile immunity against malaria..
United States Of America As Represented By The Secretary Of The Navy

Compositions, methods and uses for dengue virus serotype-4 constructs

Embodiments herein report compositions, methods and uses for dengue-4 (denv-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, denv-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject.
Takeda Vaccines, Inc.

Vaccine candidates against johne's disease

A composition and method for immunizing a mammal infected with mycobacterium are disclosed. The genes gcpe, psta, kdpc, papa2, impa, umaa1, fabg2_2, aceab, mbth2, ipqp, map0834c, cspb, lipn, and map1634 of m.
Wisconsin Alumni Research Foundation

Vaccines based on hepatitis b core antigens

The invention provides a protein comprising hepatitis b core antigen (hbcag) with a sugar attached to an e1 loop. The protein may comprise a first and a second copy of hbcag in tandem, wherein one or both copies of hbcag has a sugar attached to the e1 loop.
Iqur Limited

Method to enhance an immune response of nucleic acid vaccination

A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein..
Lipoxen Technologies Limited

Enzo Therapeutics, Inc.

. .

Chimpanzee adenoviral vector-based filovirus vaccines

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of ebolavirus (ebov) or marburg virus (marv)..
Glaxosmithkline Biologicals Sa

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals

Human sperm fibrous sheath (fs) proteins: new target antigens for use in therapeutic cancer vaccines and diagnostic screening and methods of using same

Cancer vaccines were demonstrated to be promising strategies for cancer treatment; however these strategies are limited by the paucity of target antigens that provoke an effective immune response. The inventors of the present patent application propose that sperm fibrous sheet proteins constitute a new class of potential antigens for use in the development of effective, durable cancer vaccines.
Kiromic, Llc

Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines

The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey

Bioactive conjugates for oligonucleotide delivery

Provided herein are self-delivering oligonucleotides that are characterized by efficient risc entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.. .
University Of Massachusetts

Smallpox vaccine for cancer treatment

Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response..
Stemimmune, Incorporated

Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine

Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an rsv nucleocapsid protein.
Bavarian Nordic A/s

Biodegradable nanocomplex

The present invention relates to a biodegradable nanocomplex. The biodegradable nanocomplex comprises a first electrically charged substance, a charge-redistribution substance, a second electrically charged substance and a carried substance, for holding the carried substance inside.
National Cheng Kung University

Chlamydia antigens and uses thereof

The present invention provides novel chlamydia antigens, nucleic acids encoding the antigens, and immunogenic compositions including the antigens. The present invention further provides methods of using the antigens to elicit immune responses (e.g., t cell-mediated and/or b cell-mediated immune responses).
Genocea Biosciences, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Modulated immunodominance therapy

The invention involves generating a t cell response to subdominant antigens and using the cells to therapeutically change the cellular homeostasis and nature of the immune response. In a preferred embodiment, the cells are generated outside of the patient avoiding the influence of the patient's immunologic milieu.
Geneius Biotechnology, Inc.

Vaccine

The present invention relates to a pharmaceutical combination of compositions for use in the treatment or prevention of a disease having cells bearing a target antigen as a vaccine and to a method for vaccination of a mammal, especially of a human for raising a cellular immune response directed against cells of the mammalian recipient, especially human recipient, which cells express a target antigen. The target antigen can e.g.
Medizinische Hoschschule Hannover

Recombinant listeria vaccine strains and methods of producing the same

The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant listeria strain. In one embodiment the present invention relates to a recombinant listeria strain, said recombinant listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first n-terminal fragment of an llo protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant prfa protein..
Advaxis, Inc.

Combination vaccine devices and methods of killing cancer cells

The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer..
Dana-farber Cancer Institute, Inc.

Multi-indication mrna cancer immunotherapy

Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Morphogenesis, Inc.

Antigens of pneumocystis murina and uses thereof

A surface protein of the murine fungal pathogen pneumocystis murina can be used to generate an immune response in a recipient animal or human that provides prophylactic protection and an anti-fungal activity in subjects already infected with a pneumocystis species. Further, the disclosure provides novel polypeptides or peptides derived from the p.
The University Of New Orleans

Guanosine as an immune potentiator mediated through toll receptors

Methods and compositions involving the administration of guanosine, identified as toll like receptor (tlr) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of preventing and treating cancer and infection by administration of guanosine or pro-drugs of guanosine, or a precursor of guanosine are also disclosed.
Nitor Therapeutics

3m Innovative Properties Company

. .

Modulating immune responses

Modulators of sting are able to upregulate or down regulate immune responses. Administration of such modulators can be used to treat diseases or other undesireable conditions in a subject either directly or in combination with other agents..

Chimeric viruses presenting non-native surface proteins and uses thereof

The present invention provides chimeric negative-stand rna viruses that allow a subject, e.g., an avian, to be immunized against two infectious agents by using a single chimeric virus of the invention. In particular, the present invention provides chimeric influenza viruses engineered to express and incorporate into their virions a fusion protein comprising an ectodomain of a protein of an infectious agent and the transmembrane and cytoplasmic domain of an influenza virus protein.
Icahn School Of Medicine At Mount Sinai

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnology Gmbh

Group a streptococcus vaccine

A method and composition for eliciting an immune response to group a streptococcal bacteria in a mammal is provided, which includes administering to the mammal an m protein fragment, variant or derivative thereof and a spycep protein or peptide fragment, or an antibody to the spycep protein or fragment to facilitate restoring or enhancing neutrophil activity. Also provided is an immunodominant peptide fragment of spycep..
Griffith University

Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom

Wherein a is ch or n, p is in a range from 1 to 50, r″ is a bond or -alkylene-o—, r′ is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and e is an amine- or thiol-reactive group. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.

Formulations that provide support during vaccinations and adaptive immune system response

The present invention provides formulations that support an individuals body during routine vaccination and adaptive immune response. The individuals who can benefit front these formulations are infants, children and adults.

Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance

This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided..
Mayo Foundation For Medical Education And Research

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the serex method using a cdna library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body.
Toray Industries, Inc.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the serex method using a cdna library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body.
Toray Industries, Inc.

Immune response inducer

An immunity-inducing agent comprising as an effective ingredient a specific polypeptide is disclosed. These polypeptides were isolated, by the serex method using a cdna library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing specifically in serum derived from a cancer-bearing living body.
Toray Industries, Inc.

Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel compounds useful for the treatment of degenerative and inflammatory diseases

The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune responses, such as crohn's disease, rheumatoid arthritis, psoriasis, allergic airways disease (e.g. Asthma, rhinitis), juvenile idiopathic arthritis, colitis, inflammatory bowel diseases, endotoxin-driven disease states (e.g.

Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Nkt cell ligands and methods of use

Alpha-glycosylceramide compounds capable of activating nkt cells and compositions thereof are disclosed. Methods for activating nkt cells, methods of stimulating an immune response in a subject, and methods of treating cancer, infectious diseases, autoimmune diseases and disorders, or allergy diseases or disorders with the compounds and compositions are also disclosed..
Brigham Young Unversity

Altering the immundominance hierarchy using a dna vaccine expressing conserved regions

The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus..
University Of Washington Through Its Center For Commercialization

Vaccine composition

An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (tlr4) agonist, a toll-like receptor 2/6 (tlr2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof..
Nitto Denko Corporation

Novel immunogens and methods for discovery and screening thereof

The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal t-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof.
Children's Medical Center Corporation

Specific and unique t cell responses and molecular signatures for the treatment and diagnosis of mycobacterium tuberculosis

The invention relates to novel targets for immune response modulation, treatment of tuberculosis infection and epitopes of mycobacterium tuberculosis, or subsequences, portions or modifications thereof, and methods and compounds for treatment and prevention of tuberculosis infection.. .
La Jolla Institute For Allergy And Immunology

Methods for producing an immune response to tuberculosis

Methods for producing an immune response to mycobacterium tuberculosis (mtb) are disclosed herein. In several examples, the immune response is a protective immune response.
The United States Government As Represented By The Department Of Veterans Affairs

Method for enhancing immune response in the treatment of infectious and malignant diseases

The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new dna and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response..
Taipei Veterans General Hospital

Treatment of autoimmune disorders and infections using antagonists of sgk1 activity

The present invention provides novel methods for treating th2-mediated immune disorders and enhancing th1-mediated immune responses in a subject comprising administering to the subject, a pharmaceutical composition comprising a serum-glucocorticoid regulated kinase 1 (sgk1) inhibitor and a pharmaceutically acceptable carrier. Methods for treating a wide range of autoimmune diseases are also taught.
The Johns Hopkins University

Human sirpa transgenic animals and their methods of use

The invention relates generally to compositions and methods of using transgenic non-human animals expressing human sirpα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human sirpα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function..
Yale University

Predicting immune response

Systems, methods, and non-transitory computer-readable storage media for gathering activity data describing a user's activities from one or more activity sensors and using the activity data to predict immune-response to the activity. Predicting immune-response can involve creating, personalizing, and refining immune-response prediction models based on demographic user data, activity data, blood sample data, personal genetic information..
Priobio, Llc

Gitr antigen binding proteins

Antigen binding proteins that activate gitr are provided. Nucleic acids encoding the antigen binding proteins and vectors and cells containing such nucleic acids are also provided.
Amgen Inc.

T-cell redirecting bispecific antibodies for treatment of disease

The present invention concerns compositions and methods of use of t-cell redirecting complexes, with at least one binding site for a t-cell antigen and at least one binding site for an antigen on a diseased cell or pathogen. Preferably, the complex is a dnl™ complex.
Ibc Pharmaceuticals, Inc.

Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma.
Immatics Biotechnologies Gmbh

Frictional trans-epithelial tissue disruption and collection apparatus and inducing or augmenting an immune response

The invention relates to trans-epithelial frictionally abrasive tissue sampling devices for performing biopsies and methods of inducing an immune response against a pathogen, wherein epithelial cells containing the pathogen are disrupted with the frictionally abrasive tissue sampling device to introduce the pathogen into the bloodstream of a patient.. .
Histologics, Llc

Cancer therapy

The prior art largely suggests that immune competence in a cancer patient would destroy an antigenic viral vector before it transfects host cells with a transgene-rendering therapy futile. We surprisingly found the opposite is true: cancer patients with competent immune systems obtain the most therapeutic benefit from antigenic viral vector, apparently because the antigenic viral vector, apart from transfecting cells with a transgene, induces a humoral immune response, which in turn attacks cells bearing cancer antigen.
Trizell Ltd.

Combination therapy for inducing immune response to disease

The present invention concerns combinations of two or more agents for inducing an immune response to cancer or infectious disease. Agents may include leukocyte redirecting complexes, antibody-drug conjugates, interferons (preferably interferon-α), and/or checkpoint inhibitor antibodies.
Ibc Pharmaceuticals, Inc.

Compositions and methods for using salmonella typhi toxin to induce or enhance an immune response

The invention provides compositions and methods for using plta, pltb, cdtb, or a mutant thereof, in inducing or enhancing an immune response.. .
Yale University

Replacement gene tolerizing vectors and methods of use thereof

The instant disclosure provides replacement gene tolerizing vectors and methods of using such vectors for treating individuals receiving gene therapy for muscular dystrophy, e.g., duchenne muscular dystrophy (dmd), becker muscular dystrophy (bmd), etc. Aspects of the methods include administering to the individual, in need thereof, an effective amount of a gene therapy tolerizing vaccine composition that includes a replacement gene tolerizing vector to reduce one or more symptoms of a subject's immune response to gene therapy treatment for muscular dystrophy and/or improve the efficacy of the gene therapy.
The Board Of Trustees Of The Leland Stanford Junior University

Il-15 heterodimeric protein and uses thereof

Provided is an il-15 heterodimeric protein, such as an il-15/il-15rα heterodimeric protein. The il-15 heterodimeric protein contains protein (i) and protein (ii).
Jiangsu Hengrui Medicine Co., Ltd.

Immune balance regulator

The present invention provides a novel immune balance regulator that regulates an immune balance in a living body. The immune balance regulator contains a euglena-derived material and regulates an immune balance between th1, th2, and th17, which is a balance between immune responses individually induced by th1, th2, and th17 in a living body.
Euglena Co., Ltd.

Prevention of pregnancy complications by probiotic administration

Methods for the treatment of pregnancy complications through immune modulation are disclosed. Also disclosed are probiotic compositions capable of inducing an anti-inflammatory immune response in a subject.
Therapeutic Solutions International, Inc.

Gene editing for immunological destruction of neoplasia

Disclosed are methods, protocols, and compositions of matter useful for induction and/or propagation of antitumor immune responses through gene editing of immunocytes. Stimulation of antitumor adaptive immunity is achieved through gene editing of autologous or allogeneic lymphocytes in a manner to derepress neoplasia induced suppression.
Batu Biologics Inc.

Methods for enhancing mucosal innate immune responses to and/or detection of pathogens using human milk oligosaccharides

A method for enhancing an individual's mucosal innate immune response to pathogens is disclosed. The method includes a step of administering a nutritional composition to the individual.
Abbott Laboratories

Materials and methods for improving immune responses and skin and/or mucosal barrier functions

The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of lactobacillus fermentum bacterium, or bioactive extracts thereof, derived from human microbiota and capable of growing in biofilm phenotype..
Quorum Innovations, Llc

Compositions and methods for modulating and redirecting immune responses

Provided herein are methods of modulating and redirecting an immune response. Compositions and methods for killing targeted cells in a cell population are also provided wherein, a cell population containing target cells expressing a target associated antigen and t cells are contacted with 1, 2, or more immune checkpoint antagonists and a multispecific t cell-redirecting agent that specifically binds the target associated antigen expressed on the target cells and specifically binds a t cell surface antigen..
Duke University

Superagonists and antagonists of interleukin-2

Novel human interleukin-2 (il-2) muteins or variants thereof, and nucleic acid molecules and variants thereof are provided. Methods for producing these muteins as well as methods for stimulating the immune system of an animal are also disclosed.
The Board Of Trustees Of The Leland Stanford Junior University, Office Of The General Counsel

Method of diagnosis and treatment of tumors using high intensity focused ultrasound

A method of diagnosis and treatment of tumors using high intensity focused ultrasound is provided. The method of diagnosing the presence of a tumor in a patient comprises the steps of subjecting a tumor to high intensity focused ultrasound (hifu) to cause the tumor cells to release cellular material and evaluating the cellular material for a tumor marker.
Sonacare Medical, Llc

Anti-tumor compositions and uses thereof

The present invention provides a composition for raising an immune response against a tumor. The composition comprises at least one tumor antigen, a saponin-based adjuvant, a tlr ligand and a flt3 ligand..
Csl Limited

Vaccine compositions

The present disclosure provides vaccine compositions for prophylaxis and treatment of zika virus infections comprising zika virus antigens in immunogenic compositions, and in combination of zika antigens with one or more arbovirus antigens such as chikungunya virus and japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.. .
Bharat Biotech International Limited

Compositions and methods of preparing leptospira

The present invention includes compositions and methods of preparing flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium. In one aspect, the invention includes an isolated, flagellar-coiling protein 1 (fcp1)-deficient leptospira bacterium.
Yale University

Mucin antigen vaccine

Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and cd40 ligand.
Microvax, Llc

Methods of enhancing immunity in a companion animal

Disclosed herein are methods for enhancing the immune response of a companion animal, comprising administering to a companion animal a composition comprising an effective amount of astaxanthin.. .
Mars, Incorporated

Monoclonal antibodies that modulate immunity to mtb and enhance immune clearance

The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular mtb. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to mtb and/or antibodies that are specifically reactive to mtb antigens.
Longhorn Vaccines And Diagnostics, Llc

Mutated salmonella enteriaca

A novel, mutated salmonella enterica serovar typhimurium vaccine is generated and imparts protective immunity in vaccinated animals for a range of s. Enterica serovars.
The United States Of America, As Represented By The Secretary Of Agriculture

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired.
École Polytechnique Fédérale De Lausanne (epfl)

Potentiating immune response against cancer

A method of potentiating an immune response against a cancer, non-cancerous tumor or both in a patient is provided. The method includes administering splenocytes harvested from all or a part of a patient's spleen.
Children's Hospital Of Orange County

Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy

Disclosed herein is a vaccine comprising an antigen and pd1 antibody and/or pdl1 antibody. Also disclosed herein is a method for enhancing an immune response in a subject.
Inovio Pharmaceuticals, Inc.

Immunomodulatory compounds

The present invention is based on the finding that in addition to interfering with or blocking, preventing and/or inhibiting the interaction between a pathogen and, for example, a sialic acid containing cell surface receptor, certain sialic acid binding molecules have immunomodulatory properties. The invention provides methods and uses which exploit sialic acid binding molecules in the treatment and/or prevention of disease by modulation and/or priming of the host immune response..
University Court Of The University Of St Andrews

Multivalent stable vaccine composition and methods of making same

Stable immunogenic composition capable of eliciting a robust and durable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising at least one antigen consisting of a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores. Method making and using a stable immunogenic composition capable of eliciting a stable immune response yielding a measurable increase in neutralizing antibodies at least 200 days post-administration, comprising providing an immunogenic composition comprising at least one antigen comprising a ribosome inactivating protein and at least one antigen comprising a toxin derived from bacterial spores and administering the immunogenic composition to an individual..
Soligenix, Inc.

Pharmaceutical composition comprising stem cells treated with nod2 agonist or culture thereof for prevention and treatment of immune disorders and inflammatory diseases

The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expressing nucleotide-binding oligomerization domain protein 2 (nod2) or a culture thereof. More particularly, the present invention relates to a method for suppressing immune responses or inflammatory responses of a subject, comprising the step of administering the pharmaceutical composition, the stem cells or culture thereof to the subject, a method for preparing an immunosuppressive drug or an anti-inflammatory drug using the stem cells or culture thereof, a graft comprising stem cells expressing nod2, a method for preparing the graft, a composite comprising stem cells expressing nod2, and a culture generated by culturing the nod2-expressing stem cells..
Kang Stem Biotech Co., Ltd

Methods and compositions for generating an immune response by inducing cd40 and pattern recognition receptor adapters

Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and cd40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible cd40 peptide and an inducible pattern recognition receptor adapter or adapter fragment..
Baylor College Of Medicine

Targeting agent antibody conjugates and uses thereof

Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells.
The Scripps Research Institute

Compositions and methods for modulating an immune response

Described herein are compositions for increasing il-12 production comprising igg or a fragment thereof or a variant thereof and uses of said compositions for treating cancer and infectious diseases. Also described herein are compositions for decreasing il-12 production comprising an agent that inhibits signaling mediated by interaction between fcrn and igg and uses of said compositions for treating autoimmune diseases.
The Brigham And Women's Hospital, Inc.

Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Constrained immunogenic compositions and uses therefor

A stable immunogenic or vaccine composition comprising a complex or polyhedra comprising same comprising an antigen of a pathogen or other antigen against which a immune response is sought in a human or non-human animal subject and a polyhedrin protein derived from a cytoplasmic polyhedrosis virus (cpv). Delivery of the complex to a subject in substantially polyhedral form induces an immune response thereto.
Monash University

Novel meningococcal conjugate vaccine for groups a, c, y and w135 and a preparation method thereof

The present invention provides a meningococcal conjugate vaccine for groups a, c, y and w135, which is a tetravalent conjugate vaccine comprising polysaccharide-protein conjugates obtained by respectively conjugating a capsular polysaccharide of neisseria meningitides groups a, c, y and w135 to a outer membrane vesicle protein selected from a group consisting of neisseria meningitides group b serotypes 4 and 15 outer membrane vesicle proteins. The meningococcal conjugate vaccine provided by the present invention may effectively avoid the risk of affecting the immune response to vaccines resulting from immune tolerance and competition between antigenic sites existing in multivalent conjugate vaccines prepared from a single carrier protein; the meningococcal conjugate vaccine provided by the present invention may avoid the safety risk of allergic reactions, toxicity reversion and the like which exist in conjugate vaccines prepared by using tt and dt as carrier proteins; and the meningococcal conjugate vaccine provided by the present invention may enhance immunity to neisseria meningitides group a and provide a bactericidal antibody having relatively extensive protective effect against neisseria meningitides group b.
Beijing Sanroad Biological Products Co., Ltd.

Composition for treating prostate cancer (pca)

The present invention relates to an active (immunostimulatory) composition comprising at least one rna preferably an mrna, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of psa (prostate-specific antigen), psma (prostate-specific membrane antigen), psca (prostate stem cell antigen), and steap (six transmembrane epithelial antigen of the prostate). The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (pca), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto.
Curevac Ag

Vaccine compositions and methods for restoring nkg2d pathway function against cancers

The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a mic polypeptide.. .
Dana-farber Cancer Institute, Inc.

Dna vaccines encoding heat shock proteins

A method of treating a t cell-mediated inflammatory autoimmune disease by administering to an individual in need thereof an immunogenic composition comprising a recombinant construct of a nucleic acid sequence encoding heat shock protein 90 (hsp 90), or an active fragment thereof, wherein the nucleic acid sequence is operatively linked to one or more transcription control sequences. The disease is other than insulin dependent diabetes mellitus (iddm) or rheumatoid arthritis.
Alma Bio Therapeutics

Complexes of rna and cationic peptides for transfection and for immunostimulation

The present invention relates to a complexed rna, comprising at least one rna complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (cpp), has a length of 8 to 15 amino acids and has the empirical formula (arg)l;(lys)m;(his)n;(orn)o;(xaa)x with the majority of residues being selected from arg, lys, his, orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed rna.
Curevac Ag

Enhancement of placental stem cell potency using modulatory rna molecules

Provided herein are methods of producing enhanced placental stem cells by modulatory rna molecules. Also provided herein are methods of using enhanced placental stem cells, for example, to treat individuals having a disease, disorder or condition caused by, or relating to, an unwanted or harmful immune response.
Anthrogenesis Corporation